current medical research and opinion issn

Current Medical Research and Opinion

Subject Area and Category

• Medicine (miscellaneous)

Taylor and Francis Ltd.

Publication type

03007995, 14734877

Information

How to publish in this journal

[email protected]

The set of journals have been ranked according to their SJR and divided into four equal groups, four quartiles. Q1 (green) comprises the quarter of the journals with the highest values, Q2 (yellow) the second highest values, Q3 (orange) the third highest values and Q4 (red) the lowest values.

The SJR is a size-independent prestige indicator that ranks journals by their 'average prestige per article'. It is based on the idea that 'all citations are not created equal'. SJR is a measure of scientific influence of journals that accounts for both the number of citations received by a journal and the importance or prestige of the journals where such citations come from It measures the scientific influence of the average article in a journal, it expresses how central to the global scientific discussion an average article of the journal is.

Evolution of the number of published documents. All types of documents are considered, including citable and non citable documents.

This indicator counts the number of citations received by documents from a journal and divides them by the total number of documents published in that journal. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. The two years line is equivalent to journal impact factor ™ (Thomson Reuters) metric.

Evolution of the total number of citations and journal's self-citations received by a journal's published documents during the three previous years. Journal Self-citation is defined as the number of citation from a journal citing article to articles published by the same journal.

Evolution of the number of total citation per document and external citation per document (i.e. journal self-citations removed) received by a journal's published documents during the three previous years. External citations are calculated by subtracting the number of self-citations from the total number of citations received by the journal’s documents.

International Collaboration accounts for the articles that have been produced by researchers from several countries. The chart shows the ratio of a journal's documents signed by researchers from more than one country; that is including more than one country address.

Not every article in a journal is considered primary research and therefore "citable", this chart shows the ratio of a journal's articles including substantial research (research articles, conference papers and reviews) in three year windows vs. those documents other than research articles, reviews and conference papers.

Ratio of a journal's items, grouped in three years windows, that have been cited at least once vs. those not cited during the following year.

Evolution of the percentage of female authors.

Evolution of the number of documents cited by public policy documents according to Overton database.

Evoution of the number of documents related to Sustainable Development Goals defined by United Nations. Available from 2018 onwards.

Leave a comment

Name * Required

Email (will not be published) * Required

* Required Cancel

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Follow us on @ScimagoJR Scimago Lab , Copyright 2007-2024. Data Source: Scopus®

Cookie settings

Cookie Policy

Legal Notice

Privacy Policy

Current Medical Research and Opinion

( API-Link )

Twitter : @ CMRO_Journal (3256 followers as of 2023-11-01)

Impact Factor : 2.300 (based on Web of Science 2022)

• # 42 / 149 (Q2) in Medicine, General & Internal
• # 75 / 126 (Q3) in Medicine, Research & Experimental

Partner: • University Press Alert

• ISSN: 2589-8779 (Medium online) | 2589-8760 (Medium Print)
• Journal title: Journal of Current Medical Research and Opinion
• Abbreviation: J Current Med Res Opinion
• First Year published: 2018
• Current Issue Vol. 7 No. 05 (2024)
• Frequency: Monthly| 12 per year)

Journal of Current Medical Research and Opinion is a  peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies,  and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged. 

The aim of Journal of Current Medical Research and Opinion is to provide ethical, unbiased and rapid publication of quality content that is validated by rigorous peer review. Journal aim is to serve the information needs of the clinical medicine community, to help translate medical advances into patient care and be a leader in transparency/disclosure by facilitating a collaborative and honest approach to publication.

Aims and scope:

CMRO  is the flagship medical journal. An open access, open peer-reviewed general medical journal,  CMRO outstanding and influential research in all areas of clinical practice, translational medicine, medical and health advances, public health, global health, policy, and general topics of interest to the biomedical and sociomedical professional communities. We also publish stimulating debates and reviews as well as unique forum articles and concise tutorials.  

Submission Deadlines

Volume / Issue / Month: Volume 7 Issue 05 May 2024

Initial Submission: 26.04.2024 - 26.05.2024

Submit Offline:  [email protected]

We publish innovative original research papers, review articles, case reports and short communications dealing with all the medical specialties like Anatomy, Physiology, Biochemistry, Pharmacology, Pathology, Forensic medicine, Microbiology, Community Medicine, Ophthalmology, Otorhinolaryngology, Internal Medicine, General Surgery, Paediatrics, Obstetrics and Gynaecology, Orthopaedics, Psychiatry, Radiology, Pulmonary Medicine, Dermatology and Venereal diseases, Infectious Diseases, Anaesthesia, Cardiology, Diabetes, Cancer research, Endocrinology, Urology, Neurosurgery, Geriatric Medicine, Gastroenterology, Neurology, Nephrology, Dentistry and Medical education.

Current Issue

Vol. 7 No. 05 (2024)

Original Research

The Impact of Exacerbations COPD on Respiratory Function and Quality of Life

Online First: May 2, 2024 | DOI : 10.52845/CMRO/2024/7-5-6 | Google Scholar | Abstract : 32 Cite this: Journal of Current Medical Research and Opinion , Vol. 7 No. 05 (2024), May 2, 2024 , Page 2442-2449

Adolescents’ Attitudes Towards Viral Hepatitis Transmission at Secondary Schools

Online First: May 11, 2024 | DOI : 10.52845/CMRO/2024/7-5-17 | Google Scholar | Abstract : 11 Cite this: Journal of Current Medical Research and Opinion , Vol. 7 No. 05 (2024), May 11, 2024 , Page 2510-2520

Comparing Different Training Methods in Cardiopulmonary Resuscitation CPR: A Narrative Review

Online First: May 9, 2024 | DOI : 10.52845/CMRO/2024/7-5-13 | Google Scholar | Abstract : 47 Cite this: Journal of Current Medical Research and Opinion , Vol. 7 No. 05 (2024), May 9, 2024 , Page 2499-2509

Preparatory Students' Knowledge Regarding Drug abuse in Mosul City

Online First: May 3, 2024 | DOI : 10.52845/CMRO/2024/7-5-7 | Google Scholar | Abstract : 28 Cite this: Journal of Current Medical Research and Opinion , Vol. 7 No. 05 (2024), May 3, 2024 , Page 2450-2455

Assessment of Diabetic Self-Management among Patients with Diabetic Type II

Online First: May 1, 2024 | DOI : 10.52845/CMRO/2024/7-5-1 | Google Scholar | Abstract : 55 Cite this: Journal of Current Medical Research and Opinion , Vol. 7 No. 05 (2024), May 1, 2024 , Page 2402-2410

Health Status among End Stage Kidney Disease on Hemodialysis and non-Hemodialysis Patients in Kirkuk city: Comparative Study Hemodialysis and non-Hemodialysis Patients in Kirkuk city: Comparative Study

Online First: May 6, 2024 | DOI : 10.52845/CMRO/2024/7-5-12 | Google Scholar | Abstract : 21 Cite this: Journal of Current Medical Research and Opinion , Vol. 7 No. 05 (2024), May 6, 2024 , Page 2489-2498

A Myeloproliferative Syndrome Revealed by An Eosinophilic Lung

Online First: May 2, 2024 | DOI : 10.52845/CMRO/2024/7-5-5 | Google Scholar | Abstract : 31 Cite this: Journal of Current Medical Research and Opinion , Vol. 7 No. 05 (2024), May 2, 2024 , Page 2438-2441

Knowledge and Attitude of University Students Regarding Rhinoplasty

Online First: May 1, 2024 | DOI : 10.52845/CMRO/2024/7-5-2 | Google Scholar | Abstract : 29 Cite this: Journal of Current Medical Research and Opinion , Vol. 7 No. 05 (2024), May 1, 2024 , Page 2411-2419

Assessment of Sleep Habits among Nursing Students in Mosul City/Iraq

Online First: May 1, 2024 | DOI : 10.52845/CMRO/2024/7-5-3 | Google Scholar | Abstract : 36 Cite this: Journal of Current Medical Research and Opinion , Vol. 7 No. 05 (2024), May 1, 2024 , Page 2420-2429

Nursing Students’ Attitudes about Organ Donation in University of Mosul/Iraq

Online First: May 1, 2024 | DOI : 10.52845/CMRO/2024/7-5-4 | Google Scholar | Abstract : 42 Cite this: Journal of Current Medical Research and Opinion , Vol. 7 No. 05 (2024), May 1, 2024 , Page 2430-2437

Apply Health Beliefs Model Towards of Substance Abuse

Online First: May 4, 2024 | DOI : 10.52845/CMRO/2024/7-5-9 | Google Scholar | Abstract : 36 Cite this: Journal of Current Medical Research and Opinion , Vol. 7 No. 05 (2024), May 4, 2024 , Page 2460-2467

Assessment of Nursing Students’ Attitudes Toward Obese Individuals

Online First: May 4, 2024 | DOI : 10.52845/CMRO/2024/7-5-10 | Google Scholar | Abstract : 29 Cite this: Journal of Current Medical Research and Opinion , Vol. 7 No. 05 (2024), May 4, 2024 , Page 2468-2476

Prevalence of COVID-19 among Students in Mosul University

Online First: May 4, 2024 | DOI : 10.52845/CMRO/2024/7-5-11 | Google Scholar | Abstract : 31 Cite this: Journal of Current Medical Research and Opinion , Vol. 7 No. 05 (2024), May 4, 2024 , Page 2477-2488

Risk Factors of Malnutrition of Early Childhood in Mosul City

Online First: May 10, 2024 | DOI : 10.52845/CMRO/2024/7-5-14 | Google Scholar | Abstract : 3 Cite this: Journal of Current Medical Research and Opinion , Vol. 7 No. 05 (2024), May 10, 2024 , Page 2510-2516

Assessment of Activity of Daily Livings among Patients with Heart Failure at Ibn Sina Teaching Hospital in Mosul City

Online First: May 10, 2024 | DOI : 10.52845/CMRO/2024/7-5-15 | Google Scholar | Abstract : 4 Cite this: Journal of Current Medical Research and Opinion , Vol. 7 No. 05 (2024), May 10, 2024 , Page 2517-2525

Effect of Sleep Deprivation among Night-Shift Nurses on Patient Safety

Online First: May 10, 2024 | DOI : 10.52845/CMRO/2024/7-5-16 | Google Scholar | Abstract : 4 Cite this: Journal of Current Medical Research and Opinion , Vol. 7 No. 05 (2024), May 10, 2024 , Page 2526-2532

Clinical Case Reports

Intra-Alveolar Hemorrhage Revealing Systemic Lupus Erythematosus

Online First: May 4, 2024 | DOI : 10.52845/CMRO/2024/7-5-8 | Google Scholar | Abstract : 26 Cite this: Journal of Current Medical Research and Opinion , Vol. 7 No. 05 (2024), May 4, 2024 , Page 2456-2459

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals
• Explore content
• About the journal
• Publish with us
• Sign up for alerts
• 07 May 2024

US funders to tighten oversight of controversial ‘gain of function’ research

You can also search for this author in PubMed   Google Scholar

A US policy that goes into effect next year tightens oversight of risky pathogen research conducted in biosafety facilities. Credit: Associated Press/Alamy Stock Photo

After years of deliberation, US officials have released a policy that outlines how federal funding agencies and research institutions must review and oversee biological experiments on pathogens with the potential to be misused or spark a pandemic.

The policy, which applies to all research funded by US agencies and will take effect in May 2025, broadens oversight of these experiments. It singles out work involving high-risk pathogens for special oversight and streamlines existing policies and guidelines, adding clarity that researchers have been seeking for years.

“This is a very welcome development,” says Jaime Yassif, vice-president of global biological policy and programmes at the Nuclear Threat Initiative, a research centre in Washington DC that focuses on national-security issues. “The US is the biggest funder of life sciences research [globally], so we have a moral obligation to guard against risks.”

Balancing act

Manipulating pathogens such as viruses inside an enclosed laboratory facility, sometimes by making them more transmissible or harmful (called gain-of-function research), can help scientists to assess their risk to society and develop countermeasures such as vaccines or antiviral drugs. But the worry is that such pathogens could accidentally escape the laboratory or even become weaponized by people with malicious intent.

Policymakers have had difficulty developing a clearly articulated review system that evaluates the risks and benefits of this research, while ensuring that fundamental science needed to prepare for the next pandemic and to advance medicine isn’t paralysed. The latest policy, released on 6 May by the US Office of Science and Technology Policy, is the next stage of a long-running US balancing act between totally banning high-risk pathogen research and assessing it with standards that some say are too ambiguous.

The shifting sands of ‘gain-of-function’ research

In 2014, after several accidents involving mishandled pathogens at US government laboratories, the presidential administration announced a moratorium on funding for research that could make certain pathogens — such as influenza and coronaviruses — more dangerous, given their potential to unleash an epidemic or pandemic. At the time, some researchers said the ban threatened necessary flu surveillance and vaccine research.

The government ended the moratorium in 2017, after the US National Science Advisory Board for Biosecurity (NSABB), a panel of experts that advises the US government, concluded that very few experiments posed a risk. That year, the US Department of Health and Human Services (HHS) instead implemented a review framework for proposals from scientists seeking federal funding for experiments involving potential pandemic pathogens. This framework applied to proposals to any agency housed under the HHS, including the National Institutes of Health (NIH) — the largest public funder of biomedical research in the world.

Researchers raised concerns about the transparency of this review process, and the NSABB was asked to revisit these policies and guidelines in 2020, but the COVID-19 pandemic delayed any action until 2022. During that time, the emergence of the coronavirus SARS-CoV-2 , and the ensuing debate over whether it had leaked from a lab in China, put biosafety at the top of researchers’ minds worldwide. The NIH, in particular, was scrutinized during the pandemic for its role in funding potentially risky coronavirus research. In response, some Republican lawmakers have — so far unsuccessfully — put forward legislation that would once again place a moratorium on research that might increase the transmissibility or virulence of pathogens.

Finding a balance

The latest policy aims to address concerns that have arisen over the past decade about lax oversight, ambiguous wording and lack of transparency.

It breaks potentially problematic research into two categories. The first includes research on biological pathogens or toxins that could generate knowledge, technologies or products that could be misused. The second includes research on pathogens with enhanced pandemic potential.

Research falls into the first category if it meets several criteria. For example, it must involve high-risk biological agents, such as smallpox, that are on specific lists. It must also have particular experimental outcomes, such as increasing an agent’s deadliness.

Research that falls into the second category includes pathogens intended to be modified in a way that is “reasonably anticipated” to make them more dangerous. That criterion means that even research on pathogens that are not typically considered dangerous — seasonal influenza, for example — can fall into the second category. Previously, pathogen surveillance and vaccine-development research were not subject to additional oversight in the United States; the latest policy eliminates this exception, but clarifies that both surveillance and vaccine research are “typically not within the scope” of research in the second category.

Layers of review

Scientists and their institutions are responsible for identifying research that falls into the two categories, the policy states. Once the funding agency confirms that a research proposal fits into either group, that agency will request a risk–benefit assessment and a risk-mitigation plan from the investigator and institution. If a proposal is deemed to fit into the second category, it will undergo an extra review before the project gets the green light. A report of all federally funded research that fits into the second category will be made public every year.

NIH reinstates grant for controversial coronavirus research

The directive also mandates that agencies outside the HHS that fund biological research, such as the US Department of Defense, must abide by the same rules. This is a huge step forward, says Tom Inglesby, director of the Johns Hopkins Center for Health Security in Baltimore, Maryland. But it applies only to federally funded research; the policy recommends, but does not require, that non-governmental organizations and the private sector follow the same rules.

Federal agencies and research institutions will now create their own implementation plans to comply with the policy before it goes into effect in 2025. Yassif says that the policy’s success will hinge on how these stakeholders implement it.

Nevertheless, the policy sets a worldwide standard and might inspire other countries to re-evaluate how they oversee life-sciences research, says Filippa Lentzos, a biosecurity researcher at King’s College London who chairs an advisory group for the World Health Organization (WHO) on the responsible use of life-sciences research. Later this month, at the World Health Assembly in Geneva, Switzerland, WHO member states will consider a proposal to urge nations to cooperate on developing international standards for biosecurity.

doi: https://doi.org/10.1038/d41586-024-01377-x

Reprints and permissions

Related Articles

• Research management
• Public health

Bird flu in US cows: where will it end?

News 08 MAY 24

Computationally restoring the potency of a clinical antibody against Omicron

Article 08 MAY 24

Chinese virologist who was first to share COVID-19 genome sleeps on street after lab shuts

News 01 MAY 24

Japan can embrace open science — but flexible approaches are key

Correspondence 07 MAY 24

Beware of graphene’s huge and hidden environmental costs

Countering extreme wildfires with prescribed burning can be counterproductive

France’s research mega-campus faces leadership crisis

News 03 MAY 24

My PI yelled at me and I’m devastated. What do I do?

Career Feature 02 MAY 24

Head of Operational Excellence

In this key position, you’ll be responsible for ensuring efficiency and quality in journal workflows through continuous improvement and innovation.

United States (US) - Remote

American Physical Society

Rowland Fellowship

The Rowland Institute at Harvard seeks outstanding early-career experimentalists in all fields of science and engineering.

Cambridge, Massachusetts

Rowland Institute at Harvard

Postdoctoral Fellowship: Chemical and Cell Biology

The 2-year fellowship within a project that will combine biochemical, cell biological and chemical genetic approaches to elucidate migrasome biology

Umeå, Sweden

Umeå University

Clinician Researcher/Group Leader in Cancer Cell Therapies

An excellent opportunity is available for a Group Leader with expertise in cellular therapies to join the Cancer Research program at QIMR Berghofer.

Herston, Brisbane (AU)

QIMR Berghofer

Faculty Positions at the Center for Machine Learning Research (CMLR), Peking University

CMLR's goal is to advance machine learning-related research across a wide range of disciplines.

Beijing, China

Center for Machine Learning Research (CMLR), Peking University

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies

• Conferences
• Current Issue
• Back Issues

Announcements

• Full List of Journals
• Migrate a Journal
• Special Issue Service
• Conference Publishing
• Editorial Board
• Other Journals

Journal of Health, Medicine and Nursing

The journal is a peer-reviewed, international and interdisciplinary research journal. The scope of the journal includes, physical & mental health, diet, exercise, sciences on health issues, public health, self-care, occupational health and safety issues, mechanisms in medicine, technology and manufacturing of medicines, diagosis, surgery, healthcare, nursing practice, nurse training and education, nursing ethics etc.

The journal also covers interdisciplinary research across the topics on policy, technological development, medicine industry.

About the Chief Editor of the journal

Prof. Ignat Ignatov was born on January 1, 1963 in Bulgaria. In 1989 he majored in physics from “Kliment Ohridski” Sofia University and in the same year he began his professional work in the sphere of medical biophysics. In 1996 he founded the Scientific and Research Center of Medical Biophysics (SRCMB). From 2007 Ignat Ignatov is honorable doctor in European Academy of Natural Sciences (Germany). From 2013 he is Doctor of Science and Professor in The Russian Academy for Natural History.

The publication charge of this journal: 160 USD (online publication only) or 165 USD (online publication + 2 hard copies)

IISTE is a member of  CrossRef .

The DOI of the journal is:  https://doi.org/10.7176/JHMN

Vol 115 (2024)

Table of contents.

Paper submission email: [email protected]

ISSN 2422-8419

Please add our address "[email protected]" into your email contact list.

This journal follows ISO 9001 management standard and licensed under a Creative Commons Attribution 3.0 License.

Copyright © www.iiste.org

Featured Clinical Reviews

• Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement JAMA Recommendation Statement January 25, 2022
• Evaluating the Patient With a Pulmonary Nodule: A Review JAMA Review January 18, 2022

Select Your Interests

Customize your JAMA Network experience by selecting one or more topics from the list below.

• Academic Medicine
• Acid Base, Electrolytes, Fluids
• Allergy and Clinical Immunology
• American Indian or Alaska Natives
• Anesthesiology
• Anticoagulation
• Art and Images in Psychiatry
• Artificial Intelligence
• Assisted Reproduction
• Bleeding and Transfusion
• Caring for the Critically Ill Patient
• Challenges in Clinical Electrocardiography
• Climate and Health
• Climate Change
• Clinical Challenge
• Clinical Decision Support
• Clinical Implications of Basic Neuroscience
• Clinical Pharmacy and Pharmacology
• Complementary and Alternative Medicine
• Consensus Statements
• Coronavirus (COVID-19)
• Critical Care Medicine
• Cultural Competency
• Dental Medicine
• Dermatology
• Diabetes and Endocrinology
• Diagnostic Test Interpretation
• Drug Development
• Electronic Health Records
• Emergency Medicine
• End of Life, Hospice, Palliative Care
• Environmental Health
• Equity, Diversity, and Inclusion
• Facial Plastic Surgery
• Gastroenterology and Hepatology
• Genetics and Genomics
• Genomics and Precision Health
• Global Health
• Guide to Statistics and Methods
• Hair Disorders
• Health Care Delivery Models
• Health Care Economics, Insurance, Payment
• Health Care Quality
• Health Care Reform
• Health Care Safety
• Health Care Workforce
• Health Disparities
• Health Inequities
• Health Policy
• Health Systems Science
• History of Medicine
• Hypertension
• Images in Neurology
• Implementation Science
• Infectious Diseases
• Innovations in Health Care Delivery
• JAMA Infographic
• Law and Medicine
• Leading Change
• Less is More
• LGBTQIA Medicine
• Lifestyle Behaviors
• Medical Coding
• Medical Devices and Equipment
• Medical Education
• Medical Education and Training
• Medical Journals and Publishing
• Mobile Health and Telemedicine
• Narrative Medicine
• Neuroscience and Psychiatry
• Notable Notes
• Nutrition, Obesity, Exercise
• Obstetrics and Gynecology
• Occupational Health
• Ophthalmology
• Orthopedics
• Otolaryngology
• Pain Medicine
• Palliative Care
• Pathology and Laboratory Medicine
• Patient Care
• Patient Information
• Performance Improvement
• Performance Measures
• Perioperative Care and Consultation
• Pharmacoeconomics
• Pharmacoepidemiology
• Pharmacogenetics
• Pharmacy and Clinical Pharmacology
• Physical Medicine and Rehabilitation
• Physical Therapy
• Physician Leadership
• Population Health
• Primary Care
• Professional Well-being
• Professionalism
• Psychiatry and Behavioral Health
• Public Health
• Pulmonary Medicine
• Regulatory Agencies
• Reproductive Health
• Research, Methods, Statistics
• Resuscitation
• Rheumatology
• Risk Management
• Scientific Discovery and the Future of Medicine
• Shared Decision Making and Communication
• Sleep Medicine
• Sports Medicine
• Stem Cell Transplantation
• Substance Use and Addiction Medicine
• Surgical Innovation
• Surgical Pearls
• Teachable Moment
• Technology and Finance
• The Art of JAMA
• The Arts and Medicine
• The Rational Clinical Examination
• Tobacco and e-Cigarettes
• Translational Medicine
• Trauma and Injury
• Treatment Adherence
• Ultrasonography
• Users' Guide to the Medical Literature
• Vaccination
• Venous Thromboembolism
• Veterans Health
• Women's Health
• Workflow and Process
• Wound Care, Infection, Healing
• Download PDF
• Share X Facebook Email LinkedIn
• Permissions

False Health Claims Abound, but Physicians Are Still the Most Trusted Source for Health Information

• 1 Senior Staff Writer, Medical News & Perspectives, JAMA
• 2 Manager and Senior Medical Illustrator, Editorial Graphics, JAMA and JAMA Network
• Editor's Note Introducing JAMA Data Brief Jennifer Abbasi, BA; Karen Bucher, MA, CMI; Andy Rekito, MS; Stephen Schenkel, MD, MPP; Annette Flanagin, RN, MA JAMA

The COVID-19 pandemic spotlighted a growing problem: the pervasiveness of false claims about health. To better understand how people in the US view health inaccuracies and learn about them through media use, KFF (formerly Kaiser Family Foundation), a nonprofit organization focused on health policy, tracked exposure to and beliefs about certain claims. For their Health Misinformation Tracking Pilot Poll , conducted last year, public opinion researchers at KFF asked a nationally representative sample of 2007 Black, Hispanic, and White adults about inaccurate information pertaining to COVID-19, gun violence, and reproductive health. The survey team also asked where people get their news and which sources of health information they trust.

The poll showed that trust in health care professionals crossed party lines: 95% of both Democrats and Republicans reported trusting their personal physicians to provide the right recommendations about health issues. “Doctors are particularly well positioned to be the messengers when it comes to health recommendations that people really trust,” Lunna Lopes, MSc, the lead author of the report and a senior survey analyst at KFF, told JAMA Medical News in an interview.

Most people have a fair amount of trust in the government to provide accurate information about health issues, but trust varies across political party lines. For example, 87% of Democrats reported trust in the Centers for Disease Control and Prevention compared with 49% of Republicans. State and local public health officials were trusted by 74% of Democrats and 58% of Republicans.

Overall, 96% of participants reported that they’ve heard at least 1 of the 10 inaccurate health claims listed on KFF’s survey—that measles-mumps-rubella (MME) vaccines cause autism, for example, or that ivermectin is effective against COVID-19. And while exposure to health misinformation was rampant, the percentage of people who have heard false claims and believe they’re probably or definitely true ranged from 14% to 35%. “A key takeaway that we got from the data is that people are hearing misinformation, but not many are convinced that it’s true,” Lopes said.

The results suggest that many people fall into what KFF refers to as the “malleable middle”: people who hear or read incorrect claims but are uncertain whether the information is accurate. “They say the claims are either probably true or probably false, but they’re not convinced in either direction,” Lopes explained. She emphasized that health communication needs to be more customized to reach this group. “They’re in the middle, but that doesn’t mean that they will respond to the same types of messages or interventions.”

Another key finding was that many individuals are concerned about the spread of false health claims and want more done to limit it. People overwhelmingly reported that inaccurate information about health is an important issue. In fact, 86% of respondents said false and inaccurate information in general is a major problem, and 74% reported that false claims about health specifically are a major problem.

Most respondents—regardless of their demographics or partisanship—also believe that not enough is being done to limit false claims about health. Among those polled, 78% and 68%, respectively, reported that Congress and President Joe Biden aren’t doing enough, and about 7 in 10 reported that the US news media and social media platforms need to step up.

But the idea of false claims varies from person to person. “While people agree there’s a problem, there isn’t necessarily agreement on what constitutes health misinformation, so that’s what makes addressing the problem particularly challenging,” Lopes added.

Many people reported high social media use, yet few have trust in health information published on such platforms. YouTube and Facebook were the most popular sites: 65% and 63% of respondents reported visiting the platforms every week, respectively. But trust in these sites was considerably low. Only 8% of respondents said they would have a lot of trust in health information on YouTube, and 5% would trust health information on Facebook. Twitter, now known as X, was used weekly by 21% of respondents, although only 4% would trust health information on the site. People who frequently used social media to search for health information were more likely to believe false claims about health.

When asked about traditional news sources, most respondents said they rely on local television, national networks, and digital aggregators. Overall, 62% reported regularly watching local television news, and 56% often tune into national networks like ABC, CBS, or NBC. Digital aggregators like Apple, Google, or Yahoo news followed closely behind at 55%.

But fewer than 3 in 10 adults reported having a lot of trust in each of the media sources listed in the survey. About a fourth of respondents said they would have a lot of trust in information about health issues reported by local television news or national networks, the most trusted sources.

“You’re going to have at least a little bit of trust in the news source that you’re following, but there is some skepticism there,” Lopes said.

The takeaway, Lopes said, is that although exposure to inaccurate health information remains high, so does public doubt surrounding such claims. “Most adults express uncertainty and may be open to additional information from trusted messengers, especially from their own doctors.”

Published Online: April 26, 2024. doi:10.1001/jama.2024.6837

Conflict of Interest Disclosures: Ms Lopes reported that some support for KFF’s Health Misinformation Tracking Poll Pilot was provided by the Robert Wood Johnson Foundation.

See More About

Suran M , Bucher K. False Health Claims Abound, but Physicians Are Still the Most Trusted Source for Health Information. JAMA. Published online April 26, 2024. doi:10.1001/jama.2024.6837

Manage citations:

© 2024

Artificial Intelligence Resource Center

Cardiology in JAMA : Read the Latest

Browse and subscribe to JAMA Network podcasts!

Others Also Liked

• Register for email alerts with links to free full-text articles
• Access PDFs of free articles
• Manage your interests
• Save searches and receive search alerts

This paper is in the following e-collection/theme issue:

Published on 13.5.2024 in Vol 26 (2024)

Suitability of the Current Health Technology Assessment of Innovative Artificial Intelligence-Based Medical Devices: Scoping Literature Review

Authors of this article:

There are no citations yet available for this article according to Crossref .

• Open access
• Published: 08 May 2024

The digital transformation in pharmacy: embracing online platforms and the cosmeceutical paradigm shift

• Ahmad Almeman   ORCID: orcid.org/0000-0002-6521-9463 1  

Journal of Health, Population and Nutrition volume  43 , Article number:  60 ( 2024 ) Cite this article

251 Accesses

3 Altmetric

Metrics details

In the face of rapid technological advancement, the pharmacy sector is undergoing a significant digital transformation. This review explores the transformative impact of digitalization in the global pharmacy sector. We illustrated how advancements in technologies like artificial intelligence, blockchain, and online platforms are reshaping pharmacy services and education. The paper provides a comprehensive overview of the growth of online pharmacy platforms and the pivotal role of telepharmacy and telehealth during the COVID-19 pandemic. Additionally, it discusses the burgeoning cosmeceutical market within online pharmacies, the regulatory challenges faced globally, and the private sector’s influence on healthcare technology. Conclusively, the paper highlights future trends and technological innovations, underscoring the dynamic evolution of the pharmacy landscape in response to digital transformation.

Introduction

Digital technology is driving a massive shift in the worldwide pharmacy industry with the goal of improving productivity, efficiency, and flexibility in healthcare delivery. In the pharmacy industry, implementing digital technologies like automation, computerization, and robotics is essential to cutting expenses and enhancing service delivery​​ [ 1 ]. With a predicted 14.42% annual growth rate, the digital pharmacy market is expanding significantly and is expected to reach a market volume of about $35.33 billion by 2026. This expansion reflects the pharmacy industry’s growing reliance on and promise for digital technologies​ [ 2 ].

Pharmacy services have always been focused on face-to-face communication and paper-based procedures. However, the drive for more effective, transparent, and patient-centered healthcare is clear evidence of the growing need for digital transformation. Breakthroughs like mobile communications, cloud computing, advanced analytics, and the Internet of Things (IoT) are reshaping the healthcare sector. These breakthroughs have the potential to greatly improve patient care and service delivery, as demonstrated in other industries including banking, retail, and media [ 3 ].

In the pharmacy industry, a number of significant factors are hastening this digital transition. Important concerns include the desire for cost-effectiveness, enhanced patient care, and more transparency and efficiency in medication development and manufacture. This change has been made even more rapid by the COVID-19 pandemic, which has highlighted the necessity for digital solutions to address the difficulties associated with providing healthcare in emergency situations [ 4 ].

In terms of specific technologies being adopted, artificial intelligence (AI) and machine learning are playing a pivotal role. The McKinsey Global Institute estimates that AI in the pharmaceutical industry could generate nearly $100 billion annually across the U.S. healthcare system. The use of AI and machine learning enhances decision-making, optimizes innovation, and improves the efficiency of research and clinical trials. This results in more effective patient care and a more streamlined drug development process​ [ 5 ].

The digital transformation in the pharmacy sector represents a pivotal shift in the delivery and experience of healthcare services. This evolution is more than a transient trend; it’s a fundamental alteration in the healthcare landscape [ 6 ]. The adoption of digital technologies is reshaping aspects of healthcare, including patient engagement and medication adherence, leading to enhanced healthcare outcomes. Research indicates that digital tools in pharmacy practices have resulted in more individualized and efficient patient care. Telehealth platforms, exemplified by companies like HealthTap, are being increasingly incorporated by pharmacies to augment patient care via technological solutions. The contribution of digital health technology to medication adherence is notable, employing a variety of tools such as SMS, mobile applications, and innovative devices like virtual pillboxes and intelligent pill bottles. These advancements are pivotal in addressing the critical issue of medication nonadherence in healthcare. Furthermore, digital health tools are empowering pharmacists with expanded clinical responsibilities, particularly in the management of chronic diseases like diabetes, where apps and smart devices provide essential features such as blood glucose tracking and medication reminders. This comprehensive integration of digital health into pharmacy practice signifies a transformative era in healthcare delivery and patient management [ 7 ].

Online platforms are being used increasingly by the pharmaceutical sector and educational institutions to improve efficiency, flexibility, and accessibility. The telepharmacy program at CVS Pharmacy is an example of how telepharmacy services, which provide remote counseling and prescription verification, bring pharmaceutical care to underprivileged communities [ 8 ]. Prescription accuracy and drug management are enhanced by e-prescribing software like Epic’s MyChart and digital health apps like Medisafe [ 9 ; 10 ]. Blockchain technology is also being investigated for transparent and safe supply chain management. Continuous learning and professional networking are made possible in education by Virtual Learning Environments (VLEs) like Moodle [ 11 ], simulation software like SimMan 3G Plus [ 12 ], Continuing Professional Development (CPD) platforms like the American Pharmacists Association [ 13 ], and online conference platforms, as shown in Fig.  1 . While these platforms offer significant benefits like enhanced access and cost-effectiveness, they also present challenges, including addressing the digital divide and ensuring the quality and credibility of online services to maintain professional standards and patient safety.

In this review, we summarized the digital transformation in the pharmacy sector, emphasizing the integration of online platforms and the emerging significance of cosmeceuticals. We discussed the global shift towards digital healthcare, including telehealth and online pharmacy services, and how these changes have been accelerated by the COVID-19 pandemic. The paper also examined the impact of digital technologies on pharmacy practice and education, with a focus on telepharmacy services, e-prescribing software, and digital health apps. Additionally, it addresses the challenges and opportunities presented by this transformation, including regulatory and safety concerns, and the need for continuous professional development in the digital era.

Comprehensive overview of different platforms in the pharmaceutical industry and education illustrating purposes and exemplary cases

The global impact of online pharmacy platforms

In recent years, the landscape of pharmacy practice and education has undergone a significant transformation, driven by technological advancements and catalyzed by the global COVID-19 pandemic. A study highlighting the increasing consumer trust in online medication purchases pre, during, and post-pandemic reveals a shift in consumer behavior towards online pharmacies [ 14 ]. This trend underscores a greater reliance on these platforms, where the perceived benefits significantly outweigh the perceived risks, indicating a positive reception and growing trust in digital healthcare solutions.

The adoption of telehealth, including telepharmacy, exemplifies this shift. In the United States, patient adoption of telehealth services surged from 11% in 2019 to 46%, with healthcare providers expanding their telehealth visits [ 15 ]. This shift is a reflection of how adaptable the healthcare sector is to digital platforms and how customer acceptance is increasing. The epidemic has also served as a catalyst, hastening the creation and uptake of online telepharmacy services throughout the world. The “new normal” has forced the addition of new platforms to support established sources of health information. The creation and evaluation of an online telepharmacy service in the Philippines during the pandemic serves as an example of this, demonstrating how quickly the global pharmacy industry adopted digital solutions. These services are essential for providing and elucidating pharmaceutical information within the context of primary healthcare delivery; they are not merely supplementary [ 16 ].

Simultaneously, pharmacist-led companies such as MedEssist and MedMehave, innovated digital platforms to facilitate services like flu shots or COVID-19 tests, reflecting a move towards customer-centric, digital-first services [ 17 ]. This transition enhances convenience and access to care but also introduces significant regulatory challenges. As the growth of online medicine sales disrupts traditional pharmacy markets, navigating these challenges becomes crucial for maintaining patient safety, quality standards, and fostering a trustworthy online healthcare environment [ 18 ].

Parallel to the practice changes, educational platforms for pharmacy have also evolved, especially under the impetus of the pandemic. These platforms have integrated a mix of traditional and student-centered teaching methodologies, including remote didactic lectures and on-site experiential training. The implementation of blended learning approaches, which combine remote lectures with on-site laboratory classes, reflects a broader educational trend towards hybrid models. This approach aims to leverage the advantages of both online and traditional methods, offering a more flexible and potentially more effective educational experience [ 19 ].

It takes more than just implementing new tools to integrate educational technology into pharmacy education, it also requires understanding how these technologies affect instruction and student learning. To effectively improve the educational experience, their utilization must have a purpose. There is an increasing amount of scholarly interest in this field, as evidenced by systematic reviews of the effects of new technologies on undergraduate pharmacy teaching and learning [ 20 ]. These digital platforms will probably become more significant in the future of pharmacy education, helping to mold the profession and guaranteeing that pharmacists are equipped to fulfill the ever-changing demands of the healthcare system. This development is indicative of a larger trend in the healthcare industry toward a more flexible, patient-focused, and technologically advanced environment [ 21 ].

Digital transformation in global healthcare

The recent advancements in digital transformation within global healthcare are significantly reshaping the landscape of healthcare and pharmacy services. These transformations are largely driven by the integration of digital technologies, which are redefining the tools and methods used in health, medicine, and biomedical science, ultimately aiming to create a healthier future for people worldwide [ 22 ]. In a 2018 report [ 23 ], Amazon’s potential entry into the $500 billion U.S. pharmacy market, the second-largest retail category, through mail-order and online pharmacies was highlighted as a significant industry disruptor. With licenses in at least 12 states in the US and a strategy focused on bypassing middlemen, Amazon’s historical success positions it to transform the pharmacy landscape, promising enhanced efficiency and cost savings for consumers.

One of the critical areas identified in recent research is the establishment of five priorities of e-health policy making: strategy, consensus-building, decision-making, implementation, and evaluation. These priorities emerged from stakeholders’ perceptions and are crucial for the effective integration and adoption of digital health technologies​ [ 24 ]. This holistic approach is increasingly relevant for scholars and practitioners, suggesting a focus on how multiple stakeholders implement digital technologies for management and business purposes in the healthcare sector [ 25 ]​​. The deployment of technological modalities, encompassed within five distinct clusters, can facilitate the development of a digital transformation model. This model ensures operational efficiency through several dimensions: enhanced operational efficacy by healthcare providers, the adoption of patient-centered methodologies, the integration of organizational factors and managerial implications, the refinement of workforce practices, and the consideration of socio-economic factors [ 25 ].

Studies focusing on value creation through digital means suggest healthcare as a consumer-centric realm ripe for center-edge transformations, characterized by self-service and feedback cycles. These transformations are vital in addressing inherent tensions between patients and physicians, steering the focus towards value co-creation and service-dominant logic [ 26 ]. Participatory design and decision-making approaches are emphasized for enhancing health information technology’s performance and institutional healthcare innovation. Such approaches are particularly crucial in developing national electronic medical record systems and improving chronic disease treatment through electronic health records. Additionally, telehealth research integrates patients’ perceptions, contributing to the understanding of technology, bureaucracy, and professionalism within healthcare [ 27 ].

The impact of health information technology (HIT) on operational efficiencies is profound. Empirical studies, such as those by Hong and Lee [ 28 ], Laurenza et al. [ 29 ], and Mazor et al. [ 30 ], demonstrate positive correlations between HIT and patient satisfaction, quality of care, and operational efficiency. However, challenges remain, as Rubbio et al. [ 31 ] highlight deficiencies in resilience-oriented practices for patient safety. Organizational and managerial factors in digital healthcare transformation also receive significant attention. Hikmet et al. [ 32 ] and Agarwal et al. [ 33 ] investigate the role of organizational variables and barriers in HIT adoption, whereas Cucciniello et al. [ 34 ] delve into the interdependence between implementing electronic medical records (EMR) systems and organizational conditions. Further, Eden et al. [ 35 ] and Huber and Gärtner [ 36 ] explore workforce adaptations and the implications of health information systems in hospitals that can increases transparency of work processes and accountability. Lastly, examining healthcare financialization and digital division provides an international perspective, contrasting the regulated environment in the EU with the US’s use of online medical crowdfunding as a potential solution to reduce bankruptcy [ 37 ; 38 ]. Collectively, these studies suggest a comprehensive model where stakeholders leverage digital transformation for management, enhancing operational efficiency in healthcare service providers.

Marques and Ferreira [ 39 ] performed a systematic literature review of digital transformation in healthcare, spanning the period from 1973 to 2018. Utilizing the SMARTER (Simple Multi-attribute Rating Technique Exploiting Ranks) method, 749 potential articles were analyzed, culminating in the prioritization and selection of 53 articles for detailed examination. The literature was organized into seven thematic areas: (1) Integrated management of IT in healthcare, (2) Medical images, (3) Electronic medical records, (4) IT and portable devices in healthcare, (5) Access to e-health, (6) Telemedicine, and (7) Privacy of medical data. It was observed that the predominant focus of research resides in the domains of integrated management, electronic medical records, and medical images. Concurrently, emerging trends were identified, notably the utilization of portable devices, the proliferation of virtual services, and the escalating concerns surrounding privacy. See Fig.  2 for visual representation of multifaceted digital transformation in healthcare.

Visual representation of multifaceted digital transformation in healthcare: a synthesis of provider-patient dynamics, HIT impact, and strategic management. HIT; health information technology, HC; healthcare, EMR; electronic medical records. IT; information technology, Pt.; patient

Telehealth and online pharmacy advancements in pandemic management

In the realm of online pharmacies and telehealth, digital health technologies have been instrumental in managing the COVID-19 pandemic through surveillance, contact tracing, diagnosis, treatment, and prevention. These technologies ensure that healthcare, including pharmacy services, is delivered more effectively, addressing the challenges of accessibility and timely care. The role of telemedicine and e-pharmacies, in particular, has been emphasized in improving access to care worldwide. By enabling remote consultations and drug delivery, these platforms are making healthcare more accessible, especially in regions where traditional healthcare infrastructure is limited or overstretched [ 40 ].

The Canadian Virtual Care Policy Framework advocates for the swift adoption and integration of virtual care, propelled by the COVID-19 pandemic. It emphasizes enhancing access and quality, ensuring equity and privacy, and devising appropriate remuneration models, employing a collaborative, patient-centered approach while addressing digital disparities. During the COVID-19 pandemic, Canadian provinces and territories rapidly adopted virtual health care, leading to 60% of visits being virtual by April 2020, up from 10 to 20% in 2019. However, these implementations were often temporary and not fully integrated into healthcare systems. By August 2020, virtual visits decreased to 40%, with variations across regions, while provinces and territories used temporary billing codes for these services. The framework’s “Diagnostique” provides a thorough analysis of policy enablers and strategies for virtual care, underscoring the need for comprehensive policy and partnership engagement [ 41 ]. In the context of digital transformation in pharmacy, the Hospital News article outlines the application and infrastructure of telepharmacy services in Canada, highlighting the geographical challenges and the early adoption of telepharmacy in certain regions since 2003. It notes the use of various technologies like Medication Order Management, Videoconferencing, and Remote Camera Verification. Although lacking specific quantitative data, the article underscores the necessity for expanded telepharmacy services to ensure uniform care quality across diverse locations [ 42 ].

Similarly, Telehealth offers extensive resources for patients and providers in the United States, emphasizing programs like the Affordable Connectivity Program and Lifeline to facilitate access. The Health Resources and Services Administration enhances telehealth through support services, research, and technical assistance, reflecting a significant outreach impact [ 43 ]. The Office for the Advancement of Telehealth (OAT) under Health Resources and Services Administration (HRSA) works to improve access to quality health care through integrated telehealth services in the US. It supports direct services, research, and technical assistance, with over 6,000 telehealth technical assistance requests sent to Telehealth Resource Centers and approximately 22,000 patients served [ 44 ].

Internationally, In the UK, the National Health Service (NHS) spearheads digital health and care, providing significant innovation opportunities through vast data management. Support for digital health spans various stages, from discovery with organizations like Biotechnology and Biological Sciences Research Council (BBSRC) and Intelligent Data Analysis (IDA) research group, to development with networks such as Catapults and CPRD, and delivery with entities like the Academic Health Science Networks (AHSNs) and DigitalHealth.London. Regulatory bodies like the Medicines and Healthcare products Regulatory Agency (MHRA) and NICE ensure safety and efficacy. The collaborative ecosystem involves academic, healthcare, and industry stakeholders, aiming to enhance health and care services through technology and innovation [ 45 ].

In Australia, the government’s investment of over $4 billion into COVID-19 telehealth measures has facilitated universal access to quality healthcare. This initiative has provided over 85 million telehealth services to more than 16 million patients, with approximately 89,000 healthcare providers engaging in this service delivery. From 1 January 2022, telehealth services, initially introduced in response to COVID-19, will become an ongoing part of Medicare. This will allow eligible patients across Australia continued access to general practice (GP), nursing, midwifery, and allied health services via telehealth, deemed clinically appropriate by the health professional [ 46 ].

European nations such as the Netherlands, Austria, and Italy are at the forefront of implementing cross-organizational patient records, significantly enhancing telehealth communication and facilitating cross-border healthcare. The role of strong government support in advancing telehealth is pivotal. Ursula von der Leyen, the President of the European Commission, has been a prominent advocate for eHealth. She proposed the establishment of a European Health Data Space to streamline health data exchange across member states. France, a leader in telehealth legislation for nearly a decade, has pioneered a public funding scheme for tele-expertise at a national scale. Despite these advancements, challenges like legislative barriers and the lack of consistent political direction continue to impede progress in the telehealth domain​ [ 47 ].

The Asia-Pacific region anticipates a surge in telehealth adoption driven by digital demand and pandemic-induced behavioral changes, while South East Asia exhibits widespread telehealth growth across healthcare aspects [ 48 ]. The telehealth adoption across the Asia-Pacific region has shown remarkable growth between 2019 and 2021 and is projected to continue rising by 2024. China’s adoption nearly doubled to 47% and is expected to reach 76%. Indonesia’s usage more than doubled to 51%, with a forecast of 72%. Malaysia and the Philippines both anticipate reaching a 70% adoption rate, increasing from 30% to 29%, respectively. India’s adoption is projected to more than double to 68%, while Singapore, which had a significant increase from 5 to 45%, is expected to achieve a 60% adoption rate. This trend indicates a robust uptake of telehealth services in the region [ 48 ].

Global telemedicine and E-pharmacy policy dynamics

In the context of telemedicine and e-pharmacy regulations within South East Asia, a notable distinction emerges with Singapore, Malaysia, and Indonesia being the only countries to have formalized legal frameworks governing both telemedicine practices and the dissemination of electronic information. In these countries, tele-consultation is restricted to patients already under the care of healthcare practitioners or as part of ongoing treatment, specifically in Singapore and Malaysia. Additionally, for scenarios requiring more intensive medical intervention, such as new referrals, emergency cases, or invasive procedures, both Malaysia and Indonesia mandate physical presence and face-to-face consultations, emphasizing a cautious and regulated approach to remote healthcare. In Malaysia, the regulations further stipulate that online prescriptions, excluding narcotics and psychotropic substances, are permissible solely under the continuation of care model, reflecting a judicious use of digital prescription services [ 49 ].

In Central and Eastern Europe (CEE), telemedicine has experienced substantial growth, primarily catalyzed by the COVID-19 pandemic, which necessitated rapid advancements in technology and alterations in healthcare practices. The region’s robust digital infrastructure, coupled with the innovative drive of local companies and the challenges posed by an aging demographic, has significantly contributed to this expansion. According to the European Commission’s Market Study on Telemedicine, the global telemedicine market was projected to grow annually by 14% by 2021, a rate that was likely surpassed due to the pandemic’s impact. More specifically, the Europe Telehealth Market, valued at US $6,185.4 million in 2019, is anticipated to witness an annual growth rate of 18.9% from 2020 to 2030. This trend underscores the increasing reliance on and potential of telemedicine in addressing healthcare needs in the CEE region [ 50 ].

In the Middle East, telehealth and telepharmacy, have seen varied degrees of adoption and progress. Despite attempts to reform healthcare delivery in the region, the progress of telemedicine has been somewhat slow, with certain expectations yet to be fully realized. However, there has been notable development in the use and adoption of these technologies [ 51 ]​. In a survey comparing the utilization of digital-health applications in Saudi Arabia and the United Arab Emirates (UAE), it was observed that a higher percentage of Saudi participants have utilized online pharmacy services (48%) compared to the UAE (36%). Conversely, awareness of teleconsultation services without prior use was higher in the UAE (43%) than in Saudi Arabia (35%). Retention data indicates that a significant proportion of users in both countries continue to engage with these services, with 80% of Saudi participants and 71% of UAE participants using teleconsultations at varying frequencies. Notably, a substantial majority of users in Saudi Arabia reported regular use of online pharmacies (90%), slightly higher than the UAE (78%), reflecting robust ongoing engagement with these digital health modalities. Notably, consumer adoption of telehealth products is primarily driven by time savings (48%) and convenience (47%), with 24-hour accessibility and efficacy both influencing 34% of users. Affordability and personal recommendations are also notable factors, while a wide range of options and quality are lesser but relevant considerations [ 52 ].

In response to the COVID-19 pandemic, a cross-sectional study was conducted among 391 licensed community pharmacists in the United Arab Emirates to assess the adoption and impact of telepharmacy services. The study revealed a predominant use of telepharmacy services, particularly via phone (95.6%) and messaging applications (80.0%). The findings highlighted that pharmacies with more pharmacists and those operating as part of a group or chain were more likely to implement a diverse range of telepharmacy services. The study identified significant barriers to telepharmacy adoption in individual pharmacies, including limited time, inadequate training, and financial constraints. There was a noticeable shift in service provision during the lockdown, with an increased reliance on telepharmacy, especially among pharmacies serving 50–100 patients per day. However, a reduction in services such as managing mild diseases and selling health products was observed during the lockdown period. The study concluded that telepharmacy played a pivotal role in supporting community pharmacies during the pandemic, with its expansion facilitated by the UAE’s advanced internet infrastructure, supportive health policies, and widespread digital connectivity [ 53 ]. Collectively, these insights reflect a global shift towards integrating and enhancing telehealth services as a response to emerging healthcare needs and technological advancements.

Unni et al. [ 54 ] provided an extensive review of telepharmacy initiatives adopted globally during the COVID-19 pandemic. Predominantly, virtual consultations were utilized to enable at-risk patients and others to remotely access pharmacists, thereby monitoring chronic illnesses, optimizing medication usage, and providing educational support [ 55 ]. Home delivery of medicines was widely implemented to decrease the necessity for in-person visits and mitigate exposure risks [ 56 ]. Additionally, patient education was prioritized to ensure effective management of health conditions from a distance [ 57 ]. Notably, a network of hospitals in China developed cloud-pharmacy care, allowing patients to consult pharmacists via text and the internet, while Spain utilized information and communication technologies for remote pharmaceutical care [ 58 ; 59 ]. Zero-contact pharmaceutical care, introduced in China, facilitated online medication consultations, eliminating direct contact [ 60 ]. The Kingdom of Saudi Arabia and other regions adapted new e-tools and teleprescriptions to enhance service accessibility [ 61 ]. The U.S. focused on credentialing pharmacists for telehealth to ensure competent service provision, and New Zealand implemented hotline numbers for phone consultations to further reduce physical visits [ 62 ; 63 ]. These initiatives reflect a significant shift towards innovative, technology-driven solutions in pharmaceutical care during a global health crisis. Refer to Fig.  3 for a graphical depiction of the worldwide distribution and applications of telepharmacy initiatives.

The global distribution of telepharmacy programs with an analysis of geographical distribution, technological applications, and associated benefits

Tracing the Private Sector’s Impact on Healthcare’s Technological Transformation

The role of the private sector in the fourth industrial revolution.

The World Economic Forum underscores the private sector’s leading role in digital inclusion and the acceleration of actions pertinent to the Fourth Industrial Revolution. This revolution affects economies, industries, and global issues profoundly, indicating the private sector’s critical role in driving technological advancements and digital platforms that deliver impactful healthcare solutions [ 64 ].

Mapping digital transformation in healthcare

A comprehensive analysis performed by Dal Mas et al. [ 65 ] meticulously maps the intricate terrain of digital transformation in healthcare, spotlighting the private sector’s instrumental role. Initially, the investigation encompassed an extensive array of diverse studies, leading to the identification of five main areas of digital technologies: smart health technologies, data-enabled and data collection technologies, Industry 4.0 tools and technologies, cognitive technologies, and drug & disease technologies. These domains frame the future research pathways, primarily steered by the private sector’s innovative drive. A significant proportion of the literature addresses healthcare broadly, suitable for both private and public sectors, yet a notable segment specifically focuses on the private sector’s endeavors, with a pronounced emphasis on the pharmaceutical domain [ 66 ; 67 ].

Public-private partnerships in healthcare delivery

The highlighted technologies, including digital platforms and telemedicine, exemplify the private sector’s trailblazing contributions to digital healthcare advancements. For instance, public-private partnerships (PPP) in India have emerged as a pivotal model for realizing universal healthcare (UHC), especially against the backdrop of acute healthcare shortages and urban-rural divides. Notably, mega PPP projects have successfully deployed technology-enabled remote healthcare (TeRHC), demonstrating its feasibility and impact in reaching isolated communities. These initiatives, overcoming various challenges, serve as a compelling example for global adoption, underscoring the transformative role of PPP in healthcare delivery [ 68 ].. Furthermore, a considerable majority of the literature in telemedicine underscores the necessity for profound research implications, yet a significant minority suggests policy implications [ 69 ; 70 ], reflecting a complex synergy between the private and public sectors in sculpting the digital healthcare framework [ 71 ]. This synthesis underscores the private sector’s critical influence in propelling the digital transformation in healthcare, charting a course that progressively fuses technological innovation with healthcare provision.

A study highlights Indonesia’s strategic initiatives to capitalize on telehealth business opportunities, driven by the Ministry of Research and Technology’s robust support for Technology-Based Start-up Company schemes [ 72 ]. With a demographic boon of 298 million from 2020 to 2024, escalating non-communicable diseases (71%), and a growing base of 222.4 million JKN participants, the stage is set for transformative growth. Despite a critical shortage of health workers (0.4 doctors per 1000 population), the enthusiasm for telemedicine is evident, with 71% satisfaction in hospital telemedicine and 32 million active telehealth users. The Ministry’s foresight in fostering technology start-ups, exemplified by the TEMENIN platform with its 11 health platforms, is steering Indonesia towards a future where high-quality healthcare is accessible and sustainable.

Lab@AOR: a model for PPPs in healthcare sector

The “Lab@AOR” initiative stands as a paradigmatic example of PPPs effectuating digital transformation within the healthcare sector. This strategic collaboration, between the University Hospital of Marche and Loccioni [ 73 ], a private entity, underscores the capacity of PPPs to navigate intricate challenges, stimulate international cooperation, and contribute to the development of sustainable, patient-centric healthcare solutions. Specifically, Lab@AOR was instituted to confront the nuanced challenges associated with the robotization of healthcare service delivery, highlighting the initiative’s role in fostering technological advancement through public and private sector synergy [ 74 ]. The project illustrates the evolution of Lab@AOR through three main phases: the pioneering stage, where groundwork for collaboration was laid; the nurturing stage, where collaborative exchanges were fostered; and the harvesting stage, wherein the potential of the PPP was fully unleashed. In the pioneering stage, Lab@AOR focused on a critical healthcare service component: the in-hospital preparation of medications for oncological patients. The University Hospital of Marche identified a need for innovation to improve service quality, efficiency, and safety, while Loccioni sought a real-life setting to test and refine its robotized system, APOTECAchemo [ 75 ]. This convergence of needs led to a symbiotic partnership aiming to enhance healthcare delivery through technological advancement.

During the nurturing stage, the partnership expanded the scope of APOTECAchemo to include non-oncological medications and developed additional tools like APOTECAps for manual preparation support. This phase was characterized by intensive collaboration, knowledge sharing, and continuous innovation, demonstrating the dynamic capability of the PPP to adapt and evolve in response to emerging healthcare challenges. The harvesting stage marked the international expansion of Lab@AOR, transforming it from a local initiative to an international community focused on leveraging digitalization and robotization to improve care quality and patient-centeredness. The PPP’s growth was catalyzed by its open perspective and inclusive approach, engaging entities from various cultural and institutional contexts, and fostering a network of 31 nodes across 19 countries and 3 continents.

Advancements in telehealth business models and frameworks

In their investigative study, Velayati et al. [ 76 ] delved into the articulation of emergent business models in telehealth and scrutinized the deployment of established frameworks across a variety of telehealth segments. The research spanned an extensive range of sectors, notably telemonitoring, telemedicine, mobile health, and telerehabilitation, alongside telehealth more broadly. The scope further extended to encompass niche areas such as assisted living technologies, sensor-based systems, and specific fields like mobile teledermoscopy, teleradiology, telecardiology, and teletreatment, presenting a thorough analysis of the telehealth landscape. Within the telemedicine and telehealth services sector, Barker et al. [ 77 ] introduced the Arizona Telemedicine Program (ATP) Model, a quintet-layer approach aimed at efficiently distributing telemedicine services throughout Arizona. Complementing this, Lee and Chang [ 78 ] proposed a four-component model specifically tailored for mobile health (mHealth) services pertaining to chronic kidney disease, focusing on offering a cost-effective platform for disease support and management. In the realm of telemonitoring, Dijkstra et al. [ 79 ] utilized the Freeband Business Blueprint Method (FBBM), which includes service, technological, organizational, and financial domains, to facilitate multiple telemonitoring services. Furthermore, the systemic and economic differences were explored in care coordination through Business to customer (B2C) and business (B2B) models for telemonitoring patients with chronic diseases, with the B2C model’s economic advantages were highlighted [ 80 ].

General telemedicine frameworks also received attention. Lin et al. [ 81 ] constructed a six-component framework analyzing major telemedicine projects in Taiwan, while Peters et al. [ 82 ] developed the CompBizMod Framework in Germany, encompassing value proposition, co-creation, communication and transfer, and value capture, designed to evaluate and enhance competitive advantages in telemedicine. In the specialized field of telecardiology, a comprehensive nine-component sustainable business model was crafted to facilitate mutual benefits for service providers and patients. This model emphasizes the importance of a holistic approach in ensuring the longevity and effectiveness of healthcare delivery within this domain [ 83 ]. Meanwhile, Mun et al. [ 84 ] presented a suite of five teleradiology business models aimed at providing effective, high-quality, and cost-efficient diagnoses.

The teletreatment sector saw innovative models from Kijl et al. [ 85 ], who designed a model for treating patients with chronic pain, focusing on the interrelation of components in the value network and the role of information technology. Complementarily, Fusco and Turchetti [ 86 ] introduced four models for telerehabilitation post-total knee replacement, emphasizing partnerships between care units and equipment suppliers to reduce costs and waiting lists. The mHealth and assisted living technology sector witnessed the introduction of a wearable biofeedback system model by Hidefjäll and Titkova [ 87 ], which employed Alexander Osterwalder’s Business Model Canvas and focused on a comprehensive commercialization process. Additionally, Oderanti and Li [ 88 ] presented a seven-component sustainable business model for assisted living technologies, aimed at encouraging older individuals to invest in eHealth services while reducing the pressure on health systems. These diverse clusters and models reflect the multifaceted nature of telehealth, each tailoring its approach to meet the unique demands of its domain. They collectively aim to optimize service delivery, stakeholder involvement, cost efficiency, and patient care quality, marking significant strides in the ongoing evolution of digital healthcare.

Challenges and biases in healthcare technology

One key aspect is the emergence of novel medical technologies and their potential biases. These biases are often a result of insufficient consideration of patient diversity in the development and testing phases. For example, disparities in the performance of medical devices like pulse oximeters among different racial groups have been observed, potentially due to a lack of diverse representation in clinical trials. This indicates a tendency for the development of healthcare technologies that may not adequately serve all patient populations [ 89 ]. A study on the profitability and risk-return comparison across health care industries highlights the use of return on equity (ROE) as a measure of profitability from a shareholder’s perspective. This measure combines profit margin, asset utilization, and financial leverage. The study analyzed financial data of publicly traded healthcare companies, providing insights into the financial dynamics of the healthcare sector. It revealed that while companies like Pfizer Inc. and UnitedHealth Group reported similar profitability, they had substantial differences in profit margin and asset utilization, indicating diverse financial strategies within the healthcare sector. This study underscores the complexity of financial performance in healthcare, where profitability measures need to be balanced with risk assessment and the broader impact on healthcare provision​ [ 90 ].

Additionally, an article discusses the benefits, pitfalls, and potential biases in healthcare AI. It emphasizes that as the healthcare industry adopts AI, machine learning, and other modeling techniques, it is seeing benefits for both patient outcomes and cost reduction. However, the industry must be mindful of managing the risks, including biases that may arise during the implementation of AI. Lessons from other industries can provide a framework for acknowledging and managing data, machine, and human biases in AI. This perspective is crucial in understanding how the integration of advanced technologies in healthcare can be influenced by the drive for profitability and efficiency, possibly at the expense of equitable and patient-centered care [ 91 ; 92 ].

Cosmeceuticals in the online pharmacy market

Cosmeceuticals, a term derived from the combination of cosmetics and pharmaceuticals, refer to a category of products that are formulated to provide both aesthetic improvements and therapeutic benefits. These products, typically applied topically, are designed to enhance the health and beauty of the skin, going beyond the mere cosmetic appearance. The exploration of cosmeceuticals in the online pharmacy market reveals a multifaceted and rapidly expanding industry. Bridging the gap between cosmetics and pharmaceuticals, they form a significant portion of the skincare industry. Cosmeceuticals are formulated from various ingredients, with their main categories being constantly discussed and analyzed in the scientific community [ 93 ]. They have taken a considerable share of the personal care industry globally, constituting a significant part of dermatologists’ prescriptions worldwide [ 94 ]. This surge is further fueled by increasing consumer demand for effective and safe products, including anti-aging skincare cosmeceuticals, a need which has been intensified by concerns over pollution, climate change, and the COVID-19 pandemic [ 95 ].

The global cosmeceuticals market is experiencing robust growth. Valued at USD 56.78 billion in 2022, it’s projected to expand to USD 95.75 billion by 2030, with a compound annual growth rate (CAGR) of 7.45%. This growth trajectory is propelled by the innovative integration of bioactive ingredients known for their medical benefits​ [ 96 ]. Another report confirms this upward trend, indicating the market was worth $45.56 billion in 2021 and is on a path of significant growth to USD 114 billion by 2030. The global disease burden is significantly impacted by various skin diseases, with dermatitis, psoriasis, and acne vulgaris among the most prevalent, contributing 0.38%, 0.19%, and 0.29% respectively. The pervasive nature of these conditions drives a substantial demand for effective treatments, propelling the integration of cosmeceuticals into the online pharmacy market. This integration not only offers convenient access to a range of therapeutic skincare products but also caters to the rising consumer inclination towards self-care and preventive healthcare. As a result, the online availability of cosmeceuticals is not just addressing the immediate needs of individuals suffering from skin conditions but is also reshaping the landscape of personal healthcare by making specialized treatments more accessible and customizable [ 97 ]. See Fig.  4 .

The left panel presents the market share distribution for key segments in the cosmeceuticals industry in 2021, including Skin Care Segment, and Supermarket & Specialty Stores, for Asia Pacific Revenue, with percentages for each category. The right panel displays the market value progression over time from 2021 to the projected value in 2030, with bold numbers indicating the value in billion USD for each year. The lower horizontal bar chart depicts the percentage contribution of various skin diseases to the global disease burden

Several factors are contributing to this expansion of the cosmeceuticals market. The market is driven by innovation in natural ingredients and a significant penetration of internet, smartphone, and social media applications, which attract potential consumer populations and reflect constantly changing consumer behavior [ 98 ]​​. The cosmeceuticals market’s robust CAGR and revenue share, especially in regions like Asia Pacific, further signify its burgeoning presence and potential within the global market [ 99 ]​. Integration into online pharmacies is a key aspect of this market’s evolution, offering easier access to these products for a wider customer base. As the market continues to grow, it’s anticipated that the blend of cosmeceuticals with online pharmaceutical platforms will become increasingly seamless, offering consumers a diverse range of accessible, effective, and beneficial skincare and health products. This integration is likely to be driven by the growing trend of e-commerce and digitalization in healthcare and personal care sectors.

The landscape of online pharmacies, particularly concerning cosmeceuticals, is evolving. While the overall penetration for non-specialty drugs in mail-order and online pharmacies is low, they represent a significant portion of specialty prescription revenues at 37%. Despite this, only 13% of consumers consider these as their primary pharmacy choice, indicating a growing but still emerging market​​​​. Strategies are in place to enhance the market appeal of these pharmacies, focusing on speed, convenience, and personalized experiences, such as video telehealth visits, to attract a broader consumer base [ 100 ].

The dissertation “L’Oréal Portugal: A Digital Challenge for the Active Cosmetics Division” authored by Ascenso [ 101 ] provides an in-depth examination of the impact of digital evolution on the Portuguese cosmeceutical sector and its implications for L’Oréal, a significant cosmetics company. It posits that while L’Oréal has foundational digital competencies, the rapidly evolving digital landscape presents a broad spectrum of potential risks and opportunities. The study details the operations of L’Oréal’s Active Cosmetics Division, which manages brands predominantly sold in pharmacies and parapharmacies, and explores the potential repercussions of digitalization on L’Oréal Portugal’s strategic and operational frameworks. Furthermore, the thesis highlights the expanding role of e-pharmacies and the need for legal reforms to facilitate their operation. It discusses the prevalent trends in the cosmetic industry, such as the increasing demand for natural, male-focused, and environmentally friendly products. The dissertation scrutinizes L’Oréal’s strategic pillars, including innovation, acquisition, and regional growth, emphasizing the need for the company to integrate advanced technologies and recalibrate its business methodologies in light of digital progression [ 101 ]. Although L’Oréal has initiated some digital strategies targeting consumers and pharmacies, there’s a recognized need for an intensified focus on digital marketing aimed at clients. An exploratory attempt by L’Oréal to implement an online ordering platform for pharmacies did not meet success, indicating possible industry unreadiness for such advancements. This case study serves as a critical examination of how traditional companies in the pharmaceutical and cosmetics sectors must adapt to the digital age’s challenges and opportunities [ 101 ].

In a collaborative endeavor with L’Oréal, an associated digital agency provided a comprehensive suite of services that encompasses the full management of social media pages, the development of e-commerce websites, the establishment of Customer Relationship Management (CRM) platforms tailored for pharmacies, and the execution of digital campaigns leveraging QR codes, SMS marketing, and newsletters. These digital tools confer a competitive edge, facilitating a deeper comprehension of consumer behavior and the potential to augment value extraction from customer interactions. For the laboratories, particularly those associated with cosmetics, the advantages are twofold: an increase in sell-out figures, thereby enhancing direct sales to end consumers, and a boost in sell-in metrics, reflecting a rise in transactions to pharmacies or wholesalers. The online ordering feature, as noted by João Roma, a manager at La Roche-Posay, could result in a cacophony of processes if laboratories were to individually develop distinct methods. He advocates for the utilization of pre-existing platforms, such as the established e-learning infrastructure, to spearhead ventures into the online marketplace [ 101 ].

A survey conducted specifically for L’Oréal’s e-learning platform, cosmeticaactiva.pt [ 102 ], across the Portuguese landscape garnered responses from 324 participants, comprising 71% general pharmacists, 13% technical assistants, 8% directors, 7% individuals responsible for procurement from laboratories, and 2% beauty/cosmetic advisors. The findings from this survey underscore the pervasive adoption of digital tools within the pharmacy sector: 82% of respondents affirmed the presence of their pharmacies on social media platforms, 80% reported the use of basic management software, 64% indicated the deployment of advanced management systems, 61% were conversant with online ordering systems directed at laboratories, 38% utilized a store locator, 28% had an established website presence, and a smaller segment of 12% offered online shopping facilities.

Another survey conducted within this study to evaluate the significance of dermocosmetic products in pharmacies yielded a mean importance rating of 4.38 out of 5, indicating that a majority of pharmacists consider these products to be highly important to their business operations. Factors critical to the differentiation of a proficient laboratory/supplier were innovation and cost-effectiveness, with mean scores of 1.9 and 2.7 respectively, on a scale from 1 (most important) to 5 (least important). A substantial majority of pharmacists, amounting to 81.8%, perceive their pharmacies as beacons of innovation and modernity. Detailed interviews elucidated that digital tools are indispensable in augmenting sales for cosmeceutical products by catalyzing demand—a dynamic not feasible with medicinal products. These tools are paramount in managing customer loyalty, facilitating enhanced communication with existing clients via online and mobile channels. Despite the challenges posed by digitalization, particularly in the realms of logistics and human resources, the management at L’Oréal is well-equipped to swiftly adapt to the evolving business landscape, as evidenced by the proactive adoption and integration of these digital strategies [ 101 ] as illustrated in Fig.  5 .

Results from Ascenso [ 101 ] survey assessing digital challenges for L’Oréal in the Portuguese cosmeceutical sector. Digital Tools Usage in Pharmacies (upper left) : the bar chart showing the percentage of respondents using various digital tools in pharmacies. Suppliers’ Choosing Factors (upper right) : the bar chart displaying the mean scores of factors that distinguish a good laboratory/supplier. General Pharmacists Opinion (lower left) : A line chart illustrating the mean ratings of pharmacists’ opinions on whether the pharmaceutical sector is modern, changing, conducive to innovations, adapted to consumer needs, and more developed than other sectors. Importance of Digital Development Tools for Pharmacies (lower right) : A vertical bar chart demonstrating the mean scores for the importance of different digital development tools for pharmacies

The digital transformation strategies, exemplified by companies like L’Oréal, extend beyond the mere targeting of end consumers, encompassing the perspectives of various stakeholders, including retailers. This broadened focus reflects a holistic and integrated approach to digital marketing and customer engagement, indicative of a larger trend within the market. The significance of digital channels in facilitating comprehensive customer interaction and brand development is increasingly recognized. The distinction of organizations such as L’Oréal in their digital initiatives highlights the competitive advantage that can be garnered through innovative digital strategies.

The receptiveness of industry professionals, such as pharmacists, to emerging digital trends, along with the readiness of companies to engage in non-face-to-face sales models, marks a paradigm shift in traditional sales and distribution methods. This shift is reflective of a broader market trend where digital platforms are becoming integral to the customer journey. Furthermore, the potential for online sales in specialized sectors, such as dermocosmetics, and the benefits that organizations derive from the technological advancement of their client base, underscore an escalating acknowledgment of e-commerce and digital tools as crucial elements of a business strategy. This trend, with L’Oréal as a prime example, emphasizes the broader market movement towards digital transformation, not merely as an option but as a necessity for maintaining relevance and competitiveness in an ever-evolving market landscape.

The global regulatory landscape for cosmeceuticals

Sophisticated regulatory legislation and enforcement mechanisms characterize many developed countries such as the USA, EU Member States, Canada, and Japan. These nations, along with influential organizations like the World Health Organization (WHO), significantly shape international market rules and regulations due to their market size and regulatory capacity [ 103 ]. The WHO is particularly noted for its crucial role in setting global standards, with a focus on developing and promoting international standards related to food, biological, pharmaceutical, and similar products [ 104 ]. In contrast to pharmaceuticals, the cosmetic industry necessitates a more advanced international regulatory framework due to consumers’ extensive exposure to these products. The distinction between cosmetics and pharmaceuticals varies significantly across different countries, with the USA employing a voluntary registration system for cosmetics and the EU and Japan requiring mandatory product filings prior to marketing [ 105 ]. Concerns over the safety of pharmaceutical and cosmetic products are highlighted, with an increasing consumer focus on “natural, ecological, and clean” products [ 106 ]. However, the lack of a regulatory framework for these categories underscores the need for more advanced regulations to mitigate health risks.

Intergovernmental cooperation is emphasized, with the US and EU portrayed as dominant players in the pharmaceutical and cosmetic industries, respectively. Regulatory capacity, which is essential for defining, implementing, and monitoring market rules, varies among countries and markets. This capacity depends on several factors, including staff expertise, statutory sanctioning authority, and the degree of centralization of regulatory authority [ 103 ]. The regulatory systems of the EU and US are explored, focusing on their unique approaches to medicine authorization and regulation. The European Medicines Agency (EMA) in the EU and the Food and Drug Administration (FDA) in the US serve as pivotal regulatory bodies [ 107 ; 108 ]. The EMA’s centralized procedure and the FDA’s premarket approval process are detailed, along with subsequent postmarket regulatory procedures. For instance, EU and US cosmetic regulations are compared, revealing differences in their approaches and the evolution of the EU’s regulatory landscape through various amendments and directives. In particular, directive 76/768/EC has been superseded by Regulation (EC) N° 1223/2009, serving as the principal regulatory framework for finished cosmetic products in the EU market. This regulation enhances product safety, optimizes the sector’s framework, and eases procedures to promote the internal cosmetic market. Incorporating recent technological advancements, including nanomaterials, it maintains an internationally acknowledged regime focused on product safety without altering existing animal testing prohibitions [ 109 ].

The Eurasian Economic Union’s (EAEU) regulatory framework for medicines and medical devices is detailed, including the legal framework established for regulating the circulation of these products. The conformity assessment methods, such as the EAC Declaration and the State Registration process, are required for manufacturers to demonstrate their products’ compliance with the standards [ 110 ]. Armenia is also part of the EAEU’s legal framework, which aims to unify regulations for the production and registration of pharmaceuticals and medical products by 2025. This unification is expected to reduce administrative costs for manufacturers and improve medicinal products for patients. Despite significant developments in the cosmetics industry, Armenia does not have an extensive regulatory framework for it. Prior to joining the EAEU, the only regulation concerning cosmetic products was the Order of the Minister of Health of the Republic of Armenia on “Hygiene Requirements of the Production and Safety of Perfume-Cosmetic Products.” Since joining the EAEU, Armenia has unified its national legislation with EAEU regulations, but there are challenges and gaps in the direct applicability of the EAEU’s technical regulations in the country [ 111 ].

In the context of the necessity for clear regulatory framework stems from two reasons. Firstly, cosmeceuticals - products straddling cosmetics and drugs - demand intensified regulatory attention. Examples include the 2007 FDA seizure of Jan Marini’s Age Intervention Eyelash, which contained the drug ingredient bimatoprost, and products boasting human stem cell cultured media, which claim rejuvenating effects but may pose safety risks due to minimal oversight [ 112 ]. A noted 1450% increase in FDA warnings (from 4 to 62 letters) between 2007 and 2011 and 2012–2017, with 8 targeting stem cell ingredient promotions, underscores the growing concern [ 113 ]. The FDA’s limited capacity to identify and assess potential drug-adulterated cosmetics raises concerns.

The second aspect focuses on the necessity for a more comprehensive and unbiased scientific and medical perspective in the FDA’s ingredient review process. The Personal Care Products Safety Act proposes a balanced committee formation including industry, consumer, and medical representatives, yet advocates for the inclusion of specialized professionals like chemists, dermatologists, toxicologists, and endocrinologists. Specific ingredients like diazolidinyl urea and quarternium-15, although effective antimicrobials, are flagged for potential skin allergy risks and formaldehyde release. The preservative 4-methylisothiazolinone, banned in Europe for rinse-off products, is noted for increasing allergic contact dermatitis cases in the US [ 114 ]. The lag in US cosmetic regulation compared to the EU is acknowledged, with the Personal Care Products Safety Act considered a significant advancement, albeit in need of further refinement [ 115 ].

The importance of consumer safety in the global regulatory landscape for cosmeceuticals, particularly for products that blur the line between cosmetics and pharmaceuticals, is a critical issue due to several key factors. Firstly, the cosmeceutical market is expanding rapidly, driven by new ingredients promising various skincare benefits like anti-aging and photoprotection. This growth necessitates clear regulatory guidelines to ensure that these products are safe and their claims are clinically proven. The FDA, for instance, differentiates between cosmetics and cosmeceuticals based on their intended use, particularly if a product is marketed as a cosmetic but functions in a way that affects the structure of the human body, classifying it as a cosmeceutical [ 116 ].

Secondly, the legal and regulatory distinctions between drugs and cosmetics are significant. Drugs are subject to FDA approval based on their intended use in treating diseases or affecting the body’s structure or function, whereas cosmetics are not. This difference becomes crucial when products are marketed with drug-like claims but are not regulated as drugs, potentially leading to consumer safety issues. For example, botanical cosmeceuticals, which contain natural ingredients like herbal extracts, need thorough evaluation to ensure consistency in therapeutic effects [ 117 ]. Additionally, cosmeceutical manufacturers must be careful with marketing and advertising claims to avoid legal implications. Misleading claims can lead to lawsuits and regulatory actions, as seen in past cases where companies faced consequences for unfounded product claims. Moreover, the FDA advises cosmeceutical manufacturers to follow Good Manufacturing Practices (GMP) to reduce the risk of misbranding or mislabeling. These guidelines include production practices and specific warning statement guidelines, emphasizing the importance of substantiating the safety of these products [ 118 ].

The global regulatory landscape for online pharmacy

Online pharmacies pose various risks to consumers, including the potential health hazards from counterfeit or substandard medications and the inappropriate use of prescription drugs. The regulatory landscape for these pharmacies varies significantly across nations, with some countries like the United States implementing specific laws, while others, such as France, have instituted outright bans [ 119 ]. The European Union, for instance, has implemented a mandate effective from 1 July 2015, which requires member states to adhere to legal provisions for a common logo specific to online pharmacies. This is coupled with an obligation for national regulatory authorities to maintain a registry of all registered online medicine retailers, as detailed by the European Medicines Agency [ 120 ]. Furthermore, the sale of certain medications online within the EU is permissible, contingent upon the registration of the pharmacy or retailer with respective national authorities​ [ 121 ]. Additionally, the Council of Europe’s MEDICRIME Convention introduces an international treaty that criminalizes the online sale of counterfeit medicinal products, enforcing prosecution irrespective of the country in which the crime is perpetrated [ 122 ].

Switzerland presents a unique stance, where Swissmedic strongly advises against the online purchase of medicines due to the high risk of illegal sourcing and poor quality. However, Swiss mail-order pharmacies with a valid cantonal license to operate a mail-order business are exempted from this advisory​ [ 123 ]. The Swiss Mail-Order Pharmacists Association and its affiliates, such as Zur Rose AG and MediService AG, actively advocate for a modern and equitable regulation of mail-order medicine sales​ [ 124 ]. The legislative framework is further bolstered by the Federal Act on Medicinal Products and Medical Devices, which regulates therapeutic products to guarantee their quality, safety, and efficacy​ [ 125 ]. In the Middle East, community pharmacy practice is predominantly governed by national Ministries of Public Health or equivalent governmental entities, with most community pharmacies being privately owned​ [ 126 ]. The region’s involvement in the Global Cooperation Group, which encompasses various international regulatory bodies like the EMA and USFDA, signifies a collaborative approach towards drug regulatory affairs in the MENA region [ 127 ]. Despite these advances in regulatory collaboration, it is notable that currently no specific regulations have been detected for online purchases from online pharmacies in the Middle East, highlighting a significant area for potential regulatory development. Furthermore, a notable transition is observed in pharmacy education across several Middle Eastern nations, with an inclination towards introducing Pharm.D degrees to replace traditional pharmacy degrees, reflective of evolving educational standards in the pharmaceutical field [ 128 ]. This shift in education parallels the need for updated regulatory frameworks, especially in the context of the burgeoning online pharmacy sector.

Furthermore, Australia permits the sale of both Prescription-Only Medicines (POMs) and Over-the-Counter (OTC) medications online, provided that brick-and-mortar pharmacies comply with all relevant laws and practice standards [ 129 ]. In contrast, South Korea maintains a stringent stance, prohibiting the online sale of both POMs and OTC medicines, with sales confined exclusively to physical stores registered with the Regulatory Authority (RA) [ 130 ]. China, Japan, Russia, Singapore, and Malaysia exhibit a more selective regulatory framework. China and Russia allow the online sale of OTC medicines only, with China imposing additional restrictions on third-party e-commerce platforms and Russia having introduced a draft law in December 2017 to formalize this practice [ 131 ; 132 ]. Japan permits the online sale of certain OTC medicines, explicitly excluding specific substances such as fexofenadine and loratadine [ 133 ]. Similarly, Singapore and Malaysia endorse the online sale of specific OTC medicines only, adopting a “buyers beware” approach to caution consumers about the associated risks [ 134 ; 135 ]. Lastly, the legal landscapes in India and Indonesia remain ambiguous. India’s RA has effectively banned the online sale of medicinal products, yet this prohibition lacks legislative backing. Indonesia, too, grapples with unclear regulations, leaving the legal status of online pharmacies indeterminate [ 136 ].

In response to these risks, several initiatives have been developed to guide and certify online pharmacies. In the United States, LegitScript offers certification to online pharmacies that comply with criteria such as appropriate licensing and registration [ 137 ]. Similarly, the Verified Internet Pharmacy Practice Sites (VIPPS) program, accredited by the National Association of Boards of Pharmacy, ensures pharmacies adhere to licensing requirements in the states where they dispense medications [ 138 ]. Internationally, the Health On the Net Foundation has introduced the HONcode, an ethical standard for health websites globally. This code certifies sites that provide transparent and qualified information. However, due to the absence of international harmonization, the HONcode’s certification is limited to US and Canadian pharmacies verified by VIPPS [ 139 ]. The lack of a harmonized international approach presents significant challenges. Consumers do not have access to a comprehensive, global repository of all certified pharmacies. The diverse certification schemes are not well articulated or interconnected, leading to consumer unawareness about their significance or existence. Moreover, enforcing standards across different legal jurisdictions is complex without a unified agreement. To enhance consumer protection, it is imperative to develop and promote a standardized, minimal international code of conduct for online pharmacies. Such a code would unify requirements and allow all initiatives to clarify their roles under a common framework. Adequate oversight in the borderless online pharmacy market can only be achieved through collaborative efforts. To visualize the infographic of the global regularity landscape for the online pharmacy see Fig.  6 .

Comprehensive representation of the regulatory landscape for global online pharmacies, detailing international and national initiatives, certification programs, and conventions aimed at minimizing risks associated with the purchase of medications via online platforms

Technological innovations and Future trends in global pharmacy

The global pharmacy sector is undergoing a transformative shift, driven by the rapid advancement of technological innovations. As the world becomes increasingly digital, the integration of cutting-edge technologies like Artificial Intelligence (AI) and blockchain is setting the stage for a new era in pharmaceutical care and management. These advancements promise to revolutionize the industry by enhancing efficiency, accuracy, and security, ultimately leading to improved patient outcomes and a more streamlined healthcare experience [ 140 ].

Walgreens, in partnership with Medline, a telehealth firm, has developed a platform for patient interaction with healthcare professionals via video chat. AI’s role extends to inventory management in retail pharmacies, allowing pharmacists to predict patient needs, stock appropriately, and use personalized software for patient reminders. Although not all inventory management software in retail pharmacies utilizes AI, some, like Blue Yonder’s software developed for Otto group, demonstrate the potential of AI in predicting product sales with high accuracy, thus enhancing supply chain efficiency [ 141 ; 142 ]. At the University of California San Francisco (UCSF) Medical Center, robotic technology is employed to improve patient safety in medication preparation and tracking. This technology has prepared medication doses with a notable error-free record and surpasses human capabilities in accuracy and efficiency. It prepares both oral and injectable medicines, including chemotherapy drugs, freeing pharmacists and nurses to focus on direct patient care. The automated system at UCSF receives electronic medication orders, with robotics handling the picking, packaging, and dispensing of individual doses. This system also assembles medications on bar-coded rings for 12-hour patient intervals and prepares sterile preparations for chemotherapy and intravascular syringes [ 143 ].

In the realm of global pharmacy, blockchain technology emerges as a pivotal force, driving advancements across various facets of healthcare and pharmaceuticals. At the forefront of its application is the enhancement of supply chain transparency [ 144 ]. Blockchain’s immutable ledger ensures the provenance and legitimacy of medical commodities, offering an unprecedented level of visibility from manufacturing to distribution. This is particularly vital in areas plagued by counterfeit drugs, where systems like MediLedger are instrumental in verifying the legality and essential details of medicines [ 145 ].

The utility of blockchain extends to the implementation of smart contracts — scripts processed on the blockchain that bolster transparency in medical studies and secure patient data management [ 146 ]. These contracts find extensive use in advanced medical settings, as evidenced by a blockchain-based telemonitoring system for remote patients and Dermonet, an online platform for dermatological consultation [ 147 ].

Furthermore, blockchain is revolutionizing patient care through patient-centric Electronic Health Records (EHRs). By decentralizing EHR maintenance, blockchain empowers patients with secure access to their historical and current health records [ 148 ]. Prototypes like MedRec and systems such as MeD Share exemplify how blockchain can provide complete, permanent access to clinical documents and facilitate the sharing of medical data between untrusted parties, respectively, ensuring high information authenticity and minimal privacy risks [ 149 ; 150 ]. In verifying medical staff credentials, blockchain again proves invaluable. Systems like ProCredEx, based on the R3 Corda blockchain protocol, streamline the credentialing process, offering rapid verification while allowing healthcare entities to leverage their existing data for enhanced transparency and assurance about medical staff experience [ 151 ].

The integration of blockchain with Internet of Things devices for remote monitoring marks another leap forward, significantly bolstering data security. By safeguarding the integrity and privacy of patient data collected by these devices, blockchain mitigates the risk of tampering and ensures that only authorized parties can access sensitive information [ 152 ]. Besides, a blockchain-based drug supply chain initiative, PharmaChain, utilizes AI for approaches against drug counterfeit and ensures the drug supply chain is more traceable, visible, and secure. For online pharmacies, this means a more reliable supply chain and assurance of drug authenticity, crucial for maintaining trust and safety [ 153 ].

In response to the COVID-19 pandemic, the PharmaGo platform has emerged as an innovative solution in Sri Lanka, revolutionizing the delivery of pharmacy services. As traditional pharmacies grapple with the challenges of meeting all customer needs in one location, PharmaGo addresses this by providing a comprehensive online pharmaceutical service. It allows customers to access a wide range of medications through a single platform, reducing the need to visit multiple pharmacies. Utilizing image processing technology, pharmacy owners can accurately identify prescribed medicines, while the system’s predictive analytics forecasts future drug demands, enhancing stock management. Additionally, PharmaGo’s AI-powered medical chatbot offers real-time guidance, ensuring a seamless and efficient customer experience. This platform represents a significant advancement in healthcare accessibility and pharmacy service delivery in the pandemic era [ 154 ]. In the same context, ontology-based medicine information system, enhancing search relevance through a chatbot interface was presented by Amalia et al. [ 155 ]. Addressing conventional search engines’ limitations in interpreting data relationships, it employs semantic technology to represent metadata informatively. The ontology as a knowledge base effectively delineates disease-medicine relationships, with evaluations indicating a 90% response validity from the chatbot, offering a robust reference for medical information retrieval and its semantic associations.

Future trends for the digital transformation of in the pharmaceutical sector

Future trends for the digital transformation of pharmacies globally are heavily influenced by the transformative impact of digital technologies on healthcare delivery. The integration of telemedicine, electronic health records, and mobile health applications is pivotal in enhancing patient care. These technologies are instrumental in improving data sharing and collaboration among healthcare professionals, increasing the efficiency of healthcare services. Additionally, they offer significant potential for personalized medicine through data analytics and play a crucial role in patient engagement and self-management of health. The importance of these technologies in creating a more connected and efficient healthcare system is underscored, marking a significant shift in the global healthcare landscape [ 156 ].

In the pharmaceutical sector, the COVID-19 pandemic has catalyzed a significant shift towards Pharmaceutical Digital Marketing (PDM), particularly for over-the-counter drugs. This shift focuses on utilizing online pharmacies and digital platforms for targeted advertising, directly reaching consumers. The trend towards purchasing OTC drugs online has grown, driven by the convenience and efficiency of digital channels. While PDM faces challenges like regulatory constraints and the need for digital proficiency, it offers substantial opportunities in enhancing customer engagement and precise marketing. The future of PDM is poised to be more consumer-centric, integrating advanced technologies like AI, and emphasizing personalized marketing strategies to strengthen brand engagement and customer interaction [ 157 ].

Artificial intelligence holds immense potential to revolutionize the field of pharmacy, offering numerous benefits that can significantly enhance efficiency and patient care. One of the primary applications of AI in this sector is the automation of routine tasks. By utilizing AI, pharmacies can automate critical processes such as prescription processing, checking for drug interactions, and managing inventory. This automation not only streamlines operations but also minimizes the likelihood of human error, thereby increasing the overall efficiency of pharmacies [ 158 ].

Furthermore, AI can play a pivotal role in personalized medication management. This is particularly beneficial for patients with chronic conditions such as diabetes who require careful management of their insulin dosages, as fluctuations in blood sugar levels can lead to serious complications. AI systems can monitor patients continuously, provide timely reminders for medication intake, and dynamically adjust treatment plans based on individual health data. Such personalized management ensures that patients receive optimal care tailored to their specific needs, potentially improving treatment outcomes. Incorporation of AI into electronic health records presents another significant advancement. By integrating AI with EHRs, healthcare providers can access real-time patient data. This integration empowers healthcare professionals to make more informed care decisions, enhancing the quality of patient care. Moreover, it significantly reduces the likelihood of medication errors, a critical concern in healthcare.

Likewise, AI’s capability to analyze extensive patient data is invaluable. It can identify patterns and trends in medication adherence, detect potential drug interactions, and pinpoint adverse drug reactions. These insights are crucial for healthcare professionals and researchers. By understanding these patterns, they can develop more effective medication adherence strategies and support systems, contributing to better patient outcomes and advancing the overall field of pharmaceutical care.

In the expansive realm of chemical space, the pharmaceutical industry faces the continual challenge of identifying new active pharmaceutical ingredients (APIs) for diverse diseases [ 159 ]. High throughput screening (HTS), despite its advancements in recent decades, remains resource-intensive and often yields unsuitable hits for drug development. The failure rate of investigational compounds remains high, with a study citing only a 6.2% success rate for orphan drugs progressing from phase I to market approval [ 160 , 161 ].

Machine learning presents a transformative approach to this challenge. It offers an alternative to manual HTS through in silico methodologies. ML-driven drug discovery boasts several advantages: it operates continuously, surpasses the capacity of manual methods, reduces costs by decreasing the number of physical compounds tested, and early identifies negative characteristics of compounds, such as off-target effects and sex-dependent variability [ 162 ].

A substantial advancement in the realm of machine learning has emerged from major pharmaceutical entities, notably AstraZeneca, in conjunction with research institutions. This progress is evidenced by the development of an innovative algorithm that demonstrates both time efficiency and effectiveness in the sphere of drug discovery. The recent introduction of this algorithm significantly enhances the process of determining binding affinities between investigational compounds and therapeutic targets. It surpasses traditional in silico methods in terms of performance. The application of this algorithm underscores the remarkable potential of machine learning in accelerating the identification and development of novel therapeutic agents [ 163 ].

Moreover, the proficiency of machine learning in managing vast and intricate datasets has rendered it indispensable in research focused on cancer targets, utilizing diverse and extensive datasets. This approach is fundamental in numerous drug discovery initiatives, especially those targeting various forms of cancer. A wide array of ML techniques, ranging from supervised to unsupervised learning, are employed to discern chemical attributes that are indicative of potential therapeutic efficacy against a spectrum of cancer targets. This methodology is crucial in identifying novel compounds that could be effective in cancer treatment, leveraging the rich and complex data available in oncological research [ 164 ].

The digital transformation in the pharmacy sector is significantly reshaping healthcare delivery, driven by the integration of cutting-edge technologies like Artificial Intelligence and blockchain. This transformation is marked by a substantial growth in the digital pharmacy market, with a projected annual growth rate of 14.42%, leading to a market volume of approximately $35.33 billion by 2026​​.

One major aspect of this transformation is the growing reliance on online pharmacy platforms, largely influenced by the COVID-19 pandemic. Consumer trust in online medication purchases has significantly increased, indicating a shift towards digital healthcare solutions. The adoption of telehealth services, including telepharmacy, has surged, with patient adoption in the United States increasing from 11% in 2019 to 46%. This shift towards digital-first services enhances convenience and access to care but also introduces regulatory challenges, particularly in maintaining patient safety and quality standards in the rapidly evolving online healthcare environment​​.

The cosmeceuticals market, a segment within online pharmacies, is experiencing robust growth. Cosmeceuticals, which bridge the gap between cosmetics and pharmaceuticals, have become a significant part of the skincare industry. The market, valued at USD 56.78 billion in 2022, is projected to expand to USD 95.75 billion by 2030. This expansion is driven by factors like innovation in natural ingredients and significant penetration of internet, smartphone, and social media applications. Despite the growth, the overall penetration for non-specialty drugs in mail-order and online pharmacies remains low, representing a significant portion of specialty prescription revenues. The evolving landscape of online pharmacies in the cosmeceuticals sector reflects a trend towards more accessible and customizable personal healthcare solutions​​.

Technological innovations are setting the stage for a new era in pharmaceutical care and management. AI’s role extends to areas like inventory management in retail pharmacies, where it predicts patient needs and enhances supply chain efficiency. Blockchain technology enhances supply chain transparency and legitimizes medical commodities, especially crucial in areas affected by counterfeit drugs. Blockchain also plays a vital role in patient-centric Electronic Health Records and telemonitoring systems. For instance, PharmaGo, an innovative platform developed in response to the pandemic, provides a comprehensive online pharmaceutical service, demonstrating the significant advancements in healthcare accessibility and pharmacy service delivery​​.

These technological advancements are instrumental in improving data sharing and collaboration among healthcare professionals. They offer significant potential for personalized medicine through data analytics, playing a crucial role in patient engagement and self-management of health. The future trends in the pharmaceutical sector, particularly influenced by the COVID-19 pandemic, indicate a shift towards Pharmaceutical Digital Marketing (PDM) and a more consumer-centric approach. AI’s potential in revolutionizing pharmacy includes automation of routine tasks, personalized medication management, real-time patient data access, and the identification of patterns in medication adherence and potential drug interactions​​.

Data availability

No datasets were generated or analysed during the current study.

Hole G, Hole AS, McFalone-Shaw I. Digitalization in pharmaceutical industry: what to focus on under the digital implementation process? Int J Pharmaceutics: X. 2021;3:100095.

CAS   Google Scholar  

Shambhavi. Digital Pharmacy on the rise: transforming the Pharma Sector. Brillio.com; Oct. 2022.

Champagne HA, Leclerc D. O., The road to digital success in pharma [Internet]. https://www.mckinsey.com/industries/life-sciences/our-insights/the-road-to-digital-success-in-pharma# ~:text=Mobile%20communications%2 C%20the%20cloud%2 C%20advanced,media%2 C%20retail%2 C%20and%20banking%20industries, August 1, 2015.

COVID-19 accelerated. digital transformation of the pharma industry by five years: Poll, Available from: http://www.pharmaceutical-technology.com/news/covid-19-accelerated-digital-transformation-of-the-pharma-industry-by-five-years-poll/#:~:text=Digital%20transformation%20in%20the%20pharmaceutical,powerful%20analytics%20than%20ever%20before?cf-view&acf-closed , March 9, 2021.

Raza MA, Aziz S, Noreen M, Saeed A, Anjum I, Ahmed M, Raza SM. Artificial Intelligence (AI) in pharmacy: an overview of innovations. INNOVATIONS Pharm 13 (2022).

Zhang X. Investment analysis based on intrinsic value in the Information Technology and Pharmaceutical sectors for advancements in Digital Healthcare. Finance Econ 1 (2023).

Clark M, Clark T, Bhatti A, Aungst T. The rise of digital health and potential implications for pharmacy practice. J Contemp Pharm Pract. 2017;64:32–40.

Article   Google Scholar  

Health C, Pharmacy CVS. USA, 2023.

MyChart. Epic’s MyChart software system, USA, 2023.

Medisafe MD, Companion. USA, 2023.

Moodle. Moodle open source learning management system, USA, 2023.

PLUS SG. SimMan 3G PLUS advanced emergency care patient simulators, USA, 2023.

Association AP. American Pharmacists Association, USA, 2023.

Fittler A, Ambrus T, Serefko A, Smejkalová L, Kijewska A, Szopa A, Káplár M. Attitudes and behaviors regarding online pharmacies in the aftermath of COVID-19 pandemic: at the tipping point towards the new normal. Front Pharmacol. 2022;13:1070473.

Article   PubMed   PubMed Central   Google Scholar  

Hiskey O. The era of telehealth pharmacy practice. J Am Pharmacists Association. 2022;62:10–1.

Plantado ANR, de Guzman HJd, Mariano JEC, Salvan MRAR, Benosa CAC, Robles YR. Development of an online telepharmacy service in the Philippines and analysis of its usage during the COVID-19 pandemic. J Pharm Pract. 2023;36:227–37.

Article   PubMed   Google Scholar  

Zhang PC. The future of pharmacy is intertwined with digital health innovation. Can Pharmacists Journal/Revue Des Pharmaciens Du Can. 2022;155:7–8.

Miller R, Wafula F, Onoka CA, Saligram P, Musiega A, Ogira D, Okpani I, Ejughemre U, Murthy S, Garimella S. When technology precedes regulation: the challenges and opportunities of e-pharmacy in low-income and middle-income countries. BMJ Global Health 6 (2021).

Shawaqfeh MS, Al Bekairy AM, Al-Azayzih A, Alkatheri AA, Qandil AM, Obaidat AA, Harbi SA, Muflih SM. Pharmacy students perceptions of their distance online learning experience during the COVID-19 pandemic: a cross-sectional survey study. J Med Educ Curric Dev. 2020;7:2382120520963039.

Lee CY, Lee SWH. Impact of the educational technology use in undergraduate pharmacy teaching and learning–A systematic review. Pharm Educ. 2021;21:159–68.

Strawbridge J, Hayden JC, Robson T, Flood M, Cullinan S, Lynch M, Morgan AT, O’Brien F, Reynolds R, Kerrigan SW. Educating pharmacy students through a pandemic: reflecting on our COVID-19 experience. Res Social Administrative Pharm. 2022;18:3204–9.

Lin B, Wu S. Digital transformation in personalized medicine with artificial intelligence and the internet of medical things. OMICS. 2022;26:77–81.

Article   CAS   PubMed   Google Scholar  

Company M. Trends disrupting pharmacy value pools and potential implications for the value chain, 2018.

Stoumpos AI, Kitsios F, Talias MA. Digital Transformation in Healthcare: Technology Acceptance and its applications. Int J Environ Res Public Health. 2023;20:3407.

Kraus S, Schiavone F, Pluzhnikova A, Invernizzi AC. Digital transformation in healthcare: analyzing the current state-of-research. J Bus Res. 2021;123:557–67.

Jefferies JG, Bishop S, Hibbert S. Customer boundary work to navigate institutional arrangements around service interactions: exploring the case of telehealth. J Bus Res. 2019;105:420–33.

Patrício L, Teixeira JG, Vink J. A service design approach to healthcare innovation: from decision-making to sense-making and institutional change. AMS Rev. 2019;9:115–20.

Hong KS, Lee D. Impact of operational innovations on customer loyalty in the healthcare sector. Service Bus. 2018;12:575–600.

Laurenza E, Quintano M, Schiavone F, Vrontis D. The effect of digital technologies adoption in healthcare industry: a case based analysis. Bus Process Manage J. 2018;24:1124–44.

Mazor I, Heart T, Even A. Simulating the impact of an online digital dashboard in emergency departments on patients length of stay. J Decis Syst. 2016;25:343–53.

Rubbio I, Bruccoleri M, Pietrosi A, Ragonese B. Digital health technology enhances resilient behaviour: evidence from the ward. Int J Oper Prod Manage. 2020;40:34–67.

Hikmet N, Bhattacherjee A, Menachemi N, Kayhan VO, Brooks RG. The role of organizational factors in the adoption of healthcare information technology in Florida hospitals. Health Care Manag Sci. 2008;11:1–9.

Agarwal R, Gao G, DesRoches C, Jha AK. Research commentary—the digital transformation of healthcare: current status and the road ahead. Inform Syst Res. 2010;21:796–809.

Cucciniello M, Lapsley I, Nasi G. Managing health care in the digital world: a comparative analysis. Health Serv Manage Res. 2016;29:132–42.

Eden R, Burton-Jones A, Casey V, Draheim M. Digital transformation requires workforce transformation. MIS Q Exec. 2019;18:1–17.

Google Scholar  

Huber C, Gärtner C. Digital transformations in healthcare professionals’ work: Dynamics of autonomy, control and accountability. Manage Revue. 2018;29:139–61.

Burtch G, Chan J. Investigating the relationship between medical crowdfunding and personal bankruptcy in the United States: evidence of a digital divide. MIS Quarterly (Forthcoming; 2018.

Seddon JJJM, Currie WL. Healthcare financialisation and the digital divide in the European Union: narrative and numbers. Inf Manag. 2017;54:1084–96.

Marques IC, Ferreira JJ. Digital transformation in the area of health: systematic review of 45 years of evolution. Health Technol. 2020;10:575–86.

Naik N, Hameed B, Sooriyaperakasam N, Vinayahalingam S, Patil V, Smriti K, Saxena J, Shah M, Ibrahim S, Singh A. Transforming healthcare through a digital revolution: a review of digital healthcare technologies and solutions. Front Digit Health. 2022;4:919985.

Canada. Virtual care policy framework, Canada, 2023.

Dhaliwall S. Telepharmacy services in Canada. Canada: Hospital News; 2018.

Telehealth HHSgov. Telehealth services in the United States, USA, 2023.

HRSA. Health Resources & Services Administration, USA, 2023.

UK.digital. health, Digital health and care, UK, 2023.

Australia AT, Services. Australia, 2023.

Imenokhoeva M. Telehealth in the European Union: Improving Access to Healthcare, HIMSS, EU, 2020.

Lucy d’Arville, Boulton A, Kapur V. Asia Pacific, Telehealth Adoption is expected to soar through 2024. BIAN and Company; 2022.

Intan Sabrina M, Defi IR. Telemedicine guidelines in South East Asia—a scoping review. Front Neurol. 2021;11:581649.

Wolf.Theiss. Telemedicine– the future of healthcare in Central and Eastern Europe, 2022.

Al-Samarraie H, Ghazal S, Alzahrani AI, Moody L. Telemedicine in Middle Eastern countries: Progress, barriers, and policy recommendations. Int J Med Informatics. 2020;141:104232.

Mahdi AlBasri H, Elwan P, Georgiev, Ustun A. Growth opportunities for digital health in KSA and UAE. McKinsey: McKinsey; 2022.

Ibrahim OM, Ibrahim RM, Al Meslamani AZ, Al Mazrouei N. Role of telepharmacy in pharmacist counselling to coronavirus disease 2019 patients and medication dispensing errors. J Telemed Telecare. 2023;29:18–27.

Unni EJ, Patel K, Beazer IR. Hung, Telepharmacy during COVID-19: a scoping review. Pharmacy. 2021;9:183.

Leila Shafiee Hanjani JS, Bell, Freeman CR. Undertaking medication review by telehealth. Australian J Gen Pract. 2020;49:826–31.

Bejarano AP, Santos PV, Robustillo-Cortés MdlA, Gómez ES, Rubio MDS. Implementation of a novel home delivery service during pandemic. Eur J Hosp Pharm (2020) ejhpharm–2020.

Elson EC, Oermann C, Duehlmeyer S, Bledsoe S. Use of telemedicine to provide clinical pharmacy services during the SARS-CoV-2 pandemic. Am J Health-System Pharm. 2020;77:1005–6.

Li H, Zheng S, Liu F, Liu W, Zhao R. Fighting against COVID-19: innovative strategies for clinical pharmacists. Res Social Administrative Pharm. 2021;17:1813–8.

Margusino-Framiñán L, Illarro-Uranga A, Lorenzo-Lorenzo K, Monte-Boquet E, Márquez-Saavedra E, Fernández-Bargiela N, Gómez-Gómez D, Lago-Rivero N, Poveda-Andrés JL, Díaz-Acedo R, Hurtado-Bouza JL, Sánchez-Gundín J, Casanova-Martínez C. Morillo-Verdugo, Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy Farmacia Hospitalaria. 2020;44:61–5.

PubMed   Google Scholar  

Hua X, Gu M, Zeng F, Hu H, Zhou T, Zhang Y, Shi C. Pharmacy administration and pharmaceutical care practice in a module hospital during the COVID-19 epidemic. J Am Pharmacists Association. 2020;60:431–e4381.

Asseri AA, Manna MM, Yasin IM, Moustafa MM, Roubie FM, El-Anssasy SM, Baqawie SK. Implementation and evaluation of telepharmacy during COVID-19 pandemic in an academic medical city in the Kingdom of Saudi Arabia: paving the way for telepharmacy. World J Adv Res Reviews. 2020;7:218–26.

Segal EM, Alwan L, Pitney C, Taketa C, Indorf A, Held L, Lee KS, Son M, Chi M, Diamantides E, Gosser R. Establishing clinical pharmacist telehealth services during the COVID-19 pandemic. Am J Health-System Pharm. 2020;77:1403–8.

Bukhari N, Rasheed H, Nayyer B, Babar Z-U-D. Pharmacists at the frontline beating the COVID-19 pandemic. J Pharm Policy Pract. 2020;13:8.

Smith RF. The private sector is taking the lead on enabling digital inclusion. Here’s how. in: W.E. Forum, editor, World Economic Forum, 2021.

Dal Mas F, Massaro M, Rippa P, Secundo G. The challenges of digital transformation in healthcare: an interdisciplinary literature review, framework, and future research agenda. Technovation. 2023;123:102716.

Ianculescu M, Alexandru A. Microservices–A Catalyzer for Better Managing Healthcare Data Empowerment. Stud Inf Control. 2020;29:231–42.

López-Martínez F, Núñez-Valdez ER, García-Díaz V, Bursac Z. A case study for a big data and machine learning platform to improve medical decision support in population health management. Algorithms. 2020;13:102.

Ganapathy K, Reddy S. Technology enabled remote healthcare in public private partnership mode: A story from India. Telemedicine, Telehealth and Telepresence: Principles, Strategies, Applications, and New Directions (2021) 197–233.

Gleiss A, Kohlhagen M, Pousttchi K. An apple a day–how the platform economy impacts value creation in the healthcare market. Electron Markets. 2021;31:849–76.

Bonacina S, Koch S, Meneses I, Chronaki C. Can the European EHR exchange format support shared decision making and citizen-driven health science? Public Health and Informatics, IOS; 2021. pp. 1056–60.

Samuel L, TRANSFORMING THE HEALTHCARE SYSTEM: THE PUBLIC-PRIVATE HEALTHCARE DICHOTOMY IN INDIA IN THE ERA OF DIGITAL HEALTH., Proceedings of the International Conference on Public Health, 2020, pp. 18–31.

Antarsih NR, Setyawati SP, Ningsih S, Sulaiman E, Pujiastuti N. Telehealth Business Potential in Indonesia, International Conference on Social, Economics, Business, and Education (ICSEBE 2021), Atlantis Press, 2022, pp. 73–78.

Loccioni LG. Italy, 2023.

Casprini E, Palumbo R. Reaping the benefits of digital transformation through Public-Private Partnership: A service ecosystem view applied to healthcare. Global Public Policy Gov. 2022;2:453–76.

APOTECAchemo. APOTECAchemo Advanced Robotic Chemotherapy Drug Compounding Systems, Italy, 2023.

Velayati F, Ayatollahi H, Hemmat M, Dehghan R. Telehealth business models and their components: systematic review. J Med Internet Res. 2022;24:e33128.

Barker GP, Krupinski EA, McNeely RA, Holcomb MJ, Lopez AM, Weinstein RS. The Arizona telemedicine program business model. J Telemed Telecare. 2005;11:397–402.

Lee Y-L, Chang P. Modeling a mobile health management business model for chronic kidney disease, Nursing Informatics 2016, IOS Press, 2016, pp. 1047–1048.

Dijkstra SJ, Jurriëns JA, van der Mei RD. A business model for telemonitoring services, 14th Annual High Technology Small Firms Conference, HTSF 2006, University of Twente, 2006.

Grustam AS, Vrijhoef HJ, Poulikidis V, Koymans R, Severens JL. Extending the business-to-business (B2B) model towards a business-to-consumer (B2C) model for telemonitoring patients with chronic heart failure. J Bus Models. 2018;6:106–29.

Lin T-C, Chang H-J, Huang C-C. An analysis of telemedicine in Taiwan: a business model perspective. Int J Gerontol. 2011;5:189–92.

Peters C, Blohm I, Leimeister JM. Anatomy of successful business models for complex services: insights from the telemedicine field. J Manage Inform Syst. 2015;32:75–104.

Lin S-H, Liu J-H, Wei J, Yin W-H, Chen H-H, Chiu W-T. A business model analysis of telecardiology service. Telemedicine e-Health. 2010;16:1067–73.

Mun SK, Tohme WG, Platenberg RC, Choi I. Teleradiology and emerging business models. J Telemed Telecare. 2005;11:271.

Kijl B, Nieuwenhuis LJ, Veld RM, Hermens HJ. and M.M. Vollenbroek-Hutten, Deployment of e-health services–a business model engineering strategy. Journal of telemedicine and telecare 16 (2010) 344–353.

Fusco F, Turchetti G, Interactive Business Models for Telerehabilitation after Total Knee Replacement.: Preliminary Results from Tuscany, Bioinformatics and Biomedical Engineering: Third International Conference, IWBBIO 2015, Granada, Spain, April 15–17, 2015. Proceedings, Part II 3, Springer, 2015, pp. 502–511.

Hidefjäll P, Titkova D. Business model design for a wearable biofeedback system, pHealth, 2015, pp. 213–224.

Oderanti FO, Li F. A holistic review and framework for sustainable business models for assisted living technologies and services. Int J Healthc Technol Manage. 2016;15:273–307.

Valbuena VS, Seelye S, Sjoding MW, Valley TS, Dickson RP, Gay SE, Claar D, Prescott HC, Iwashyna TJ. Racial bias and reproducibility in pulse oximetry among medical and surgical inpatients in general care in the Veterans Health Administration 2013-19: multicenter, retrospective cohort study. BMJ 378 (2022).

Bai G, Rajgopal S, Srivastava A, Zhao R. Profitability and risk-return comparison across health care industries, evidence from publicly traded companies 2010–2019. PLoS ONE. 2022;17:e0275245.

Article   CAS   PubMed   PubMed Central   Google Scholar  

McCall CJ, DeCaprio D, Gartner J. The Measurement and Mitigation of Algorithmic Bias and Unfairness in Healthcare AI Models Developed for the CMS AI Health Outcomes Challenge. medRxiv (2022) 2022.09. 29.22280537.

Hsueh P-YS. Ecosystem of patient-centered research and information System Design, Personal Health Informatics: patient participation in Precision Health. Springer; 2022. pp. 329–51.

Martin KI, Glaser DA. Cosmeceuticals: the new medicine of beauty. Mo Med. 2011;108:60.

PubMed   PubMed Central   Google Scholar  

Pandey A, Jatana GK, Sonthalia S, Cosmeceuticals SP. StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC., Treasure Island (FL) ineligible companies. Disclosure: Gurpoonam Jatana declares no relevant financial relationships with ineligible companies. Disclosure: Sidharth Sonthalia declares no relevant financial relationships with ineligible companies., 2023.

Morganti P, Morganti G, Gagliardini A, Lohani A. From cosmetics to innovative cosmeceuticals—Non-woven tissues as New Biodegradable Carriers. Cosmetics. 2021;8:65.

Article   CAS   Google Scholar  

Market C. Fortune Business Insights., Cosmeceuticals Market, 2023.

LLP SMR. Global Cosmeceuticals Market, A $95.75 Billion Industry Opportunity by 2030., 2022.

R.a. Markets, Global Cosmeceuticals Market - Outlook & Forecast 2023–2028, 2023.

Research SM. Industry Report and Statistics (Facts & Figures) - Number of Users, Price, Demand & Sales Analysis by Product & Distribution Channel, 2021.

Company M. Meeting changing consumer needs: The US retail pharmacy of the future, 2023.

Ascenso FNS. L’Oréal Portugal: a digital challenge for the active cosmetics division, 2016.

cosmeticaactiva. L’Oreal E-Learning Platform in Portugal, 2023.

Bach D, Newman AL. Governing lipitor and lipstick: capacity, sequencing, and power in international pharmaceutical and cosmetics regulation. Rev Int Polit Econ. 2010;17:665–95.

Organization WH. Quality assurance of pharmaceuticals. a compendium of guidelines and related materials: Good manufacturing practices and inspection, 2007.

Rai S, Gupta A, Punetha V. Regulations of Cosmetics across the Globe. Applied Clinical Research. Clin Trials Regul Affairs. 2015;2:137–44.

Natural VLAMBERT. & Organic Living; Say ‘No’ To Chemicals For A Healthy Life. in: Raconteur, editor, 2016.

Agency EM. The European regulatory system for medicines, 2023.

FDA, Food and Drug Adimenstration in the United States of America, 2023.

Cosmetics I, Market. Industry, Entrepreneurship and SMEs, EU, European Commission 2023.

EEU EEU. TECHNICAL REGULATION ON THE SAFETY OF COSMETICS AND PERFUMERY, 2015.

Danghyan L. Armenian regulatory framework of the cosmetics and pharmaceutical industries, and its compliance with international regulations. Whether the existing regulatory framework of cosmetics and pharmaceutical industries complies with international best practice and ensures product safety and consumer protection. American University of Armenia; 2020.

TGA. Australian Public Assessment Report for Bimatoprost, 2017.

Kwa M, Welty LJ, Xu S. Adverse events reported to the US Food and Drug Administration for cosmetics and personal care products. JAMA Intern Med. 2017;177:1202–4.

DeKoven JG, Warshaw EM, Belsito DV, Sasseville D, Maibach HI, Taylor JS, Marks JG, Fowler JF, Mathias CT, DeLeo VA. North American contact dermatitis group patch test results 2013–2014. Dermatitis. 2017;28:33–46.

Janetos TM, Kwa M, Xu S. Regulation of cosmetics. JAMA Intern Med. 2018;178:1000–1.

Daum C. Self-Regulation in the Cosmetic Industry: A Necessary Reality or a Cosmetic Illusion? 2006.

Schaffer S, Reading Our Lips.: The History of Lipstick Regulation in Western Seats of Power, 2006.

Lincoln JE. Overview of the us fda gmps: good manufacturing practice (gmp)/quality system (qs) regulation (21 CFR part 820). J Validation Technol. 2012;18:17.

van der Heijden I, Pletneva N, Boyer C. How to protect consumers against the risks posed by the online pharmacy market. Swiss Med Inf 29 (2013).

Agency EM. Buying medicines online, 2015.

Union E. Buying medicine online, 2023.

ISPE. Regulating Online Pharmacies & Medicinal Product E-Commerce, 2019.

Swissmedic. Guideline on medicines and the Internet, 2020.

Kulali H. Online Pharmacy in Switzerland: A Full Guide. 2023, Pharmapidya, 2023.

Swissmedic. Current law, 2019.

El Hajj MS, Mekkawi R, Elkaffash R, Saleh R, Awaisi AE, Wilbur K. Public attitudes towards community pharmacy in Arabic speaking Middle Eastern countries: a systematic review. Res Social Administrative Pharm. 2021;17:1373–95.

DelveInsight. The Regulatory process for drug approval in the MENA region, DelveInsight, 2019.

Sallom H, Abdi A, Halboup AM, Başgut B. Evaluation of pharmaceutical care services in the Middle East Countries: a review of studies of 2013–2020. BMC Public Health. 2023;23:1364.

P.B.o. Australia, Guidelines for Dispensing of Medicines., 2019.

Center KLT. Statutes of the Republic of Korea. Pharmaceutical Affairs Act; 2016.

Goryachev I. Russia Federation: Telemedicine Law in Russia, Mondaq, 2018.

Jing M. China FDA stops online med sales, 2016.

L.a.W. o.J. Ministry of Health, List of Sales Sites for over-the-counter Drugs, 2020.

H.S.A.o, Singapore. Dangers of Buying Health Products Online, 2023.

M.o.H.o. Malaysia, Buying Medicines Online: Beware., 2023.

Ganapathy N. India’s pharmacies do battle with online rivals Straitimes, India, 2017.

LegitScript LS. Industry-Leading Certification, 2023.

NABP. The Verified Internet Pharmacy Practice Sites, 2012.

Boyer C, Baujard V, Geissbuhler A. Evolution of health web certification through the HONcode experience. Stud Health Technol Inf. 2011;169:53–7.

Tagde P, Tagde S, Bhattacharya T, Tagde P, Chopra H, Akter R, Kaushik D, Rahman MH. Blockchain and artificial intelligence technology in e-Health. Environ Sci Pollut Res. 2021;28:52810–31.

Walgreen. Convenient virtual care., 2023.

Group O. Otto Group, 2023.

U.o.C.S, Francisco, New UCSF. Robotic Pharmacy Aims to Improve Patient Safety, 2011.

Narayanaswami C, Nooyi R, Govindaswamy SR, Viswanathan R. Blockchain anchored supply chain automation. IBM J Res Dev. 2019;63:7: 1–7.

Khezr S, Moniruzzaman M, Yassine A, Benlamri R. Blockchain technology in healthcare: a comprehensive review and directions for future research. Appl Sci. 2019;9:1736.

Xia Q, Sifah EB, Asamoah KO, Gao J, Du X, Guizani M. MeDShare: Trust-less medical data sharing among cloud service providers via blockchain. IEEE access 5 (2017) 14757–14767.

Mannaro K, Pinna A, Marchesi M. Crypto-trading: Blockchain-oriented energy market, 2017 AEIT International Annual Conference, IEEE, 2017, pp. 1–5.

Rallapalli S, Minalkar A. Improving Healthcare-Big Data Analytics for. J Adv Inform Technol 7 (2016).

Wang H, Song Y. Secure cloud-based EHR system using attribute-based cryptosystem and blockchain. J Med Syst. 2018;42:152.

Cyran MA. Blockchain as a foundation for sharing healthcare data. Blockchain Healthc Today (2018).

Funk E, Riddell J, Ankel F, Cabrera D. Blockchain technology: a data framework to improve validity, trust, and accountability of information exchange in health professions education. Acad Med. 2018;93:1791–4.

Khan PW, Byun Y. A blockchain-based secure image encryption scheme for the industrial internet of things. Entropy. 2020;22:175.

Gomasta SS, Dhali A, Tahlil T, Anwar MM, Ali ABMS. PharmaChain: Blockchain-based drug supply chain provenance verification system. Heliyon. 2023;9:e17957.

Gamage RG, Bandara NS, Diyamullage DD, Senadeera KU, Abeywardena KY, Amarasena N. PharmaGo-An Online Pharmaceutical Ordering Platform, 2021 3rd International Conference on Advancements in Computing (ICAC), IEEE, 2021, pp. 365–370.

Amalia A, Sipahutar PYC, Elviwani E, Purnamasari F. Chatbot Implementation with Semantic Technology for Drugs Information Searching System. Journal of Physics: Conference Series 1566 (2020) 012077.

Trenfield SJ, Awad A, McCoubrey LE, Elbadawi M, Goyanes A, Gaisford S, Basit AW. Advancing pharmacy and healthcare with virtual digital technologies. Adv Drug Deliv Rev. 2022;182:114098.

Anis MS, Hassali MA. Pharmaceutical marketing of over-the-counter drugs in the current digital era: a review. Pharm Sci Asia 49 (2022).

Khan O, Parvez M, Kumari P, Parvez S, Ahmad S. The future of pharmacy: how AI is revolutionizing the industry. Intell Pharm. 2023;1:32–40.

Moshawih S, Hadikhani P, Fatima A, Goh HP, Kifli N, Kotra V, Goh KW, Ming LC. Comparative analysis of an anthraquinone and chalcone derivatives-based virtual combinatorial library. A cheminformatics proof-of-concept study. J Mol Graph Model. 2022;117:108307.

Moshawih S, Goh HP, Kifli N, Idris AC, Yassin H, Kotra V, Goh KW, Liew KB, Ming LC. Synergy between machine learning and Natural products Cheminformatics: application to the lead Discovery of anthraquinone derivatives. Chemical Biology & Drug Design; 2022.

Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20:273–86.

Moshawih S, Goh HP, Kifli N, Darwesh MAE, Ardianto C, Goh KW, Ming LC. Identification and optimization of TDP1 inhibitors from anthraquinone and chalcone derivatives: consensus scoring virtual screening and molecular simulations. J Biomol Struct Dynamics (2023) 1–25.

Moore JH, Margreitter C, Janet JP, Engkvist O, de Groot BL, Gapsys V. Automated relative binding free energy calculations from SMILES to ∆∆G. Commun Chem. 2023;6:82.

Moshawih S, Lim AF, Ardianto C, Goh KW, Kifli N, Goh HP, Jarrar Q, Ming LC. Target-based small Molecule Drug Discovery for Colorectal Cancer: a review of Molecular pathways and in Silico studies. Biomolecules. 2022;12:878.

Download references

Acknowledgements

The researcher would like to thank the Deanship of Scientific Research, Qassim University for funding the publication of this project.

Deanship of Scientific Research, Qassim University

Author information

Authors and affiliations.

Department of Pharmacology, College of Medicine, Qassim University, Buraydah, Saudi Arabia

Ahmad Almeman

You can also search for this author in PubMed   Google Scholar

Contributions

Conceived the conceptual framework, Wrote the paper, Designed search strategies, Critically reviewed the manuscript for important intellectual content: A.A.

Corresponding author

Correspondence to Ahmad Almeman .

Ethics declarations

Ethical approval and consent to participate.

Not applicable.

Consent for publication

Competing interests.

The author declares no competing interest.

Additional information

Publisher’s note.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ . The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Cite this article.

Almeman, A. The digital transformation in pharmacy: embracing online platforms and the cosmeceutical paradigm shift. J Health Popul Nutr 43 , 60 (2024). https://doi.org/10.1186/s41043-024-00550-2

Download citation

Received : 14 February 2024

Accepted : 09 April 2024

Published : 08 May 2024

DOI : https://doi.org/10.1186/s41043-024-00550-2

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

• Digital transformation
• Healthcare technology
• Cosmeceuticals
• Global health
• Patient care
• 2019 novel coronavirus
• Drug safety

Journal of Health, Population and Nutrition

ISSN: 2072-1315

• Submission enquiries: [email protected]
• General enquiries: [email protected]

How cannabis and psilocybin might help some of the 50 million Americans who are experiencing chronic pain

Assistant Professor of Anesthesiology, University of Michigan

Disclosure statement

Kevin F. Boehnke receives funding from the National Institutes of Health, the State of Michigan Veteran Marijuana Research Program, and has received grants from Tryp Therapeutics and Journey Biosciences. He is affiliated with Doctors for Drug Policy Reform as an unpaid expert. He also has received honoraria for speaking at conferences as well as for participating in a podcast on fibromyalgia from the European Medical Journal funded by Viatris Inc.

University of Michigan provides funding as a founding partner of The Conversation US.

View all partners

The U.S. Drug Enforcement Agency announced in late April 2024 that it plans to ease federal restrictions on cannabis , reclassifying it from a Schedule I drug to the less restricted Schedule III, which includes drugs such as Tylenol with codeine, testosterone and other anabolic steroids . This historic shift signals an acknowledgment of the promising medicinal value of cannabis .

The move comes in tandem with growing interest in the use of psilocybin, the active component in magic mushrooms, for treatment of depression , chronic pain and other conditions . In 2018 and 2019, the U.S. Food and Drug Administration granted a breakthrough therapy designation to psilocybin , meant to expedite drug development given that preliminary studies suggest it may have substantial therapeutic value over currently available therapies for treatment-resistant depression and major depressive disorder .

Both of these developments represent a dramatic change from long-standing federal policy around these substances that has historically criminalized their use and blocked or delayed research efforts into their therapeutic potential.

As an assistant professor of anesthesiology and a pain researcher, I study alternative pain management options , including cannabis and psychedelics.

I also have a personal stake in improving chronic pain treatment: In early 2009 I was diagnosed with fibromyalgia , a condition characterized by widespread pain throughout the body, sleep disturbances and generalized sensory sensitivity.

I see cannabis and psilocybin as promising therapies that can contribute to bridging that need. Given that an estimated 50 million Americans have chronic pain – meaning pain that persists for three months or more – I want to help understand how to effectively use cannabis and psilocybin as potential tools for pain management.

Cannabis versus other pain medications

Cannabis , also known as marijuana, is an ancient medicinal plant. Cannabis-based medicines have been used for at least 5,000 years for applications such as arthritis and pain control during and after surgery.

This use extended through antiquity to modern times, with contemporary cannabis-based medications for treating certain seizure disorders , promoting weight gain for HIV/AIDS-related anorexia and treating nausea during chemotherapy .

As with anything you put in your body, cannabis does have health risks: Driving while high may increase risk of accidents. Some people develop cyclical vomiting , while others develop motivation or dependence problems , especially with heavy use at younger ages .

That said, lethal overdoses from cannabis are almost unheard of . This is remarkable considering that nearly 50 million Americans use it each year .

In contrast, opioids, which are often prescribed for chronic pain, have contributed to hundreds of thousands of overdose deaths over the past few decades. Even common pain medications like nonsteroidal anti-inflammatory drugs, such as ibuprofen, cause tens of thousands of hospitalizations and thousands of deaths each year from gastrointestinal damage.

Furthermore, both opioids and nonopioid pain medications have limited effectiveness for treating chronic pain. Medications used for chronic pain can provide small to moderate pain relief in some people, but many ultimately cause side effects that outweigh any gains.

These safety issues and limited benefit have led many people with chronic pain to try cannabis as a chronic pain treatment alternative. Indeed, in survey studies , my colleagues and I show that people substituted cannabis for pain medications often because cannabis had fewer negative side effects .

However, more rigorous research on cannabis for chronic pain is needed. So far, clinical trials – considered the gold standard – have been short in length and focused on small numbers of people . What’s more, my colleagues and I have shown that these studies employ medications and dosing regimes that are far different from how consumers actually use products from state-licensed cannabis dispensaries. Cannabis also causes recognizable effects such as euphoria, altered perceptions and thinking differently, so it is difficult to conduct double-blind studies .

Despite these challenges, a group of cannabis and pain specialists published a proposed guideline for clinical practice in early 2024 to synthesize existing evidence and help guide clinical practice. This guideline recommended that cannabis products be used when pain is coupled with sleep problems, muscle spasticity and anxiety. These multiple benefits mean that cannabis could potentially help people avoid taking a separate medication for each symptom.

Traditional hurdles to studying cannabis

Since the Controlled Substance Act was passed in 1970, the federal government has designated cannabis as a Schedule I substance , along with other drugs such as heroin and LSD. Possession of these drugs is criminalized, and under the federal definition they have “no currently accepted medical use, with a high potential for abuse.” Because of this designation and the limits placed on drug manufacturing, cannabis is very difficult to study .

State and federal regulatory barriers also delay or prevent studies from being approved and conducted. For example, I can purchase cannabis from state-licensed dispensaries in my hometown of Ann Arbor, Michigan. As a scientist, however, it is very challenging to legally test whether these products help pain .

Reclassifying cannabis as a Schedule III drug has the potential to substantially open up this research landscape and help overcome these barriers.

The emerging role of psychedelics

Psychedelics, such as psilocybin-containing mushrooms, occupy an eerily similar scientific and political landscape as cannabis. Used for thousands of years for ceremonial and healing purposes , psilocybin is also classified as a Schedule I drug. It can cause substantial changes in sensory perception, mood and sense of self that can lead to therapeutic benefits. And, like cannabis, psilocybin has minimal risk of lethal overdose .

Clinical trials combining psilocybin with psychotherapy in the weeks before and after taking the drug report substantial improvements in symptoms of psychiatric conditions such as treatment-resistant depression and alcohol use disorder .

Risks are typically psychological. A small number of people report suicidal thoughts or self-harm behaviors after taking psilocybin. Some also experience heightened openness and vulnerability , which can be exploited by therapists and lead to abuse .

There are few published clinical trials of psilocybin therapy for chronic pain, although many are ongoing , including a pilot study for fibromyalgia conducted by our team at the University of Michigan. This treatment may help people develop a healthier relationship with their pain by eliciting greater acceptance of it and decreasing rumination often related to negative thoughts and feelings around pain.

As with cannabis, some states, such as Colorado and Oregon , have decriminalized psilocybin and are building infrastructure to increase accessibility to psilocybin-assisted therapy. One recent analysis suggests that if psychedelics follow a similar legalization pattern to cannabis, the majority of states will legalize psychedelics between 2034 and 2037 .

Challenges ahead

These ancient yet relatively “new” treatments offer a unique glimpse into the messy intersection of drugs, medicine and society. The justifiable excitement about cannabis and psilocybin has led to state policies that have increased access for some people, yet federal criminalization and substantial barriers to scientific investigation remain. In the years ahead, I hope to contribute toward pragmatic studies that work within these difficult parameters.

For example, our team developed a coaching intervention to help veterans use commercially available cannabis products to more effectively treat their pain. Coaches emphasize how judicious use can minimize side effects while maximizing benefits. Should our approach work, health care providers and cannabis dispensaries everywhere could use this treatment to help clients in chronic pain.

Approaches like these can supplement more traditional clinical trials to help researchers determine whether these drug classes offer benefit and whether they have comparable or less harm than current treatments. As our society connects to the rich history of healing using these ancient drugs, these proposed changes may offer safer and substantive options for the 50 million Americans living with chronic pain.

This article is part of Legal cannabis turns 10, a series examining the impact of a decade of recreational cannabis use.

You may be interested in:

Cannabis legalization has led to a boom in potent forms of the drug that present new hazards for adolescents

Mounting research points to health harms from cannabis, THC and CBD use during pregnancy, adolescence and other periods of rapid development

Cannabis-derived products like delta-8 THC and delta-10 THC have flooded the US market – two immunologists explain the medicinal benefits and potential risks

• Chronic pain
• Psychedelics
• Pain management

Lecturer / Senior Lecturer - Marketing

Communications and Engagement Officer, Corporate Finance Property and Sustainability

Assistant Editor - 1 year cadetship

Executive Dean, Faculty of Health

Lecturer/Senior Lecturer, Earth System Science (School of Science)